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Anxiety is one of the most prevalent mental health problems around the world. 
Despite a number of widely available interventions, it can take weeks or months to 
see effects, and nearly half of individuals may not respond. In an effort to better 
understand response rates, a large body of evidence indicates the most consistent 
predictor of treatment outcomes is activity in the anterior cingulate cortex (ACC). 
Although activity in ACC can be measured by medial frontal theta event related 
potentials (ERPs) at a finer temporal resolution, these neurophysiological components 
have not been evaluated as predictors of treatment response. There is also a lack of 
research on the functional networks associated with ACC treatment prediction, 
despite implications for prefrontal engagement of cognitive control processes. The 
present study aimed to examine these gaps in the literature by using task-based 
electroencephalography (EEG) and medial frontal theta negativities (MFTN) as 
  
predictors of anxiety sensitivity treatment response. Using amplitude as well as 
functional connectivity measures (i.e., inter-channel phase synchrony), baseline 
MFTN (i.e., Theta-FN, Theta-N2) were assessed as predictors of treatment response 
at mid-treatment, 1-week post treatment, and 6 months post treatment. Subjects 
underwent a baseline EEG before completing three sessions of a computerized 
cognitive behavioral intervention. Contrary to the hypothesis, findings revealed 
MFTN amplitude did not predict treatment response. However, medial to lateral 
prefrontal theta phase synchrony demonstrated significant prediction effects, such that 
lower phase synchrony was associated with greater symptom improvement at mid-
treatment, 1-week post treatment, and 6 months post treatment. This effect was 
specific to certain task conditions (i.e., gain feedback and go stimuli), as well as to the 
combined anxiety and depression treatment group. Results demonstrated accuracy 
and consistency of treatment prediction, as well as incremental validity after 
controlling for self-report measures. Finally, results provide additional support for a 
convergent medial frontal theta process, and suggest that low engagement of 
regulatory and proactive control mechanisms may be predictive of better response to 
cognitive behavioral interventions. This work represents a novel finding that may 
contribute to the improvement in treatment efficacy by serving as a target for future 
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Chapter 1: Introduction 
Anxiety and its impact on society 
 
Approximately 42 million American adults live with an anxiety disorder, 
making anxiety one of the most prevalent mental health problems in the United States 
and around the world (Collins et al., 2011; Kessler, Petukhova, Sampson, Zaslavsky, 
& Wittchen, 2012). According to data provided in the National Comorbidity Survey, 
the most prevalent lifetime disorders are specific phobia (15.6%), major depressive 
disorder (MDD; 14.4.%), and social phobia (10.7%), followed by post-traumatic 
stress disorder (PTSD; 5.7%) and generalized anxiety disorder (GAD; 4.3%). Of the 
above mentioned disorders, four of the five fall under the spectrum of anxiety 
psychopathology, underscoring its pervasiveness in society.  
With such high prevalence rates, the effects of anxiety on the individual and 
society remain substantial. Using GAD as an example, in primary care settings it is 
estimated that 22% of those who complain of anxiety problems have a diagnosis of 
GAD, but fewer than 20% of sufferers will experience remission of symptoms 
(Wittchen, 2002). For the individual, GAD is a persistent and severe mental disorder 
characterized by six months or more of excessive worrying, hypervigilance, and 
somatic symptoms, along with subjective feelings of loss of control. Further, these 
symptoms often translate to social and work impairment. It has been suggested that 
the level of social disability associated with GAD is as severe as seen with chronic 
somatic diseases (Kessler et al., 2001), and approximately 34% of patients with GAD 




al., 2000). Additional evidence from an Australian study found the burden of mental 
illness (particularly GAD and depression) was third after the burden of heart disease 
and cancer (Andrews et al., 2000). In these epidemiological studies, ‘burden’ is 
defined as a conglomerate measure estimated in disability-adjusted life years 
(DALYs) lost, expressed as the cumulative number of years lost due to ill-health.  
Economically, anxiety disorders contribute significantly to mental health 
costs. Some estimates suggest anxiety disorders cost $46.6 billion in direct (i.e., 
patient visits, professional services, medication costs, etc.) and indirect costs (i.e., lost 
income, lost productivity, mortality etc.), accounting for 31.5% of the total cost of 
mental illness in America (DuPont et al., 1996).  
Anxiety is also associated with higher rates of suicidal ideation and suicidal 
behavior. Based on information provided by the National Comorbidity Survey, it is 
estimated that 70% of individuals with a previous suicide attempt had at least one 
anxiety disorder (Sareen, J. et. al., 2005). Even after controlling for comorbidity and 
other risk factors for suicide, anxiety remains a significant predictor. 
Taken together, the presence of anxiety psychopathology is a significant 
factor that leads to individual and societal burden in the form of debilitating 
symptoms, medical costs, and even high rates of suicide. As such, there is a need for 
more research in this domain, particularly studies that may offer insight into anxiety 
treatment outcomes. 
Importance of predicting treatment response 
 As alluded to above, remission rates for anxiety remain minimal. Remarkably, 




after treatment (Wittchen, 2002). Even with some of the most effective 
pharmacotherapy treatments for anxiety, response rates are estimated at 
approximately 60%, indicating that nearly half of the individuals undergoing 
treatment do not show any change in symptom severity (Nimatoudis et al., 2004; 
Pollack, 2001).  
Because such a large number of individuals do not respond to currently 
available treatments for mood and anxiety disorders, there is a need for 1) more 
effective treatments, and 2) more informed and individualized treatment selection 
(Simon & Perlis, 2010). While the former includes pharmaceutical drug discovery 
and development, the latter is an emerging field of research focused on identifying 
pre-treatment measures that predict an individual’s likelihood of response to an 
intervention. Identifying predictors of treatment response is critical since many 
treatments take weeks or months to see effects, resulting in prolonged suffering and 
potential for worsening of symptoms. Therefore, patients and clinicians would benefit 
from having objective pre-treatment measures that predict which patients will and 
will not respond to a given treatment.  
The ability to predict treatment outcome before or shortly after a treatment is 
initiated could mean significant improvement in individualized treatment selection, 
and ultimately improvement in the efficacy of treatments. Indeed, several 
sociodemographic and clinical measures have been identified in this regard, including 
history of failed treatments (Ellis, Zarate, Luckenbaugh, & Furey, 2014), pre-
treatment symptom severity (Connor, Hidalgo, Crockett, Malik, Katz, & Davidson, 




Worthington, 2000; Tukel, Bozkurt, Polat, Genc, & Atli, 2006), comorbidity with 
other disorders (Baer, Jenike, Black, Treece, Rosenfeld, & Greist, 1992), and 
avoidant personality traits (Chambless, Tran, & Glass, 1997). As a complementary 
and arguably more objective approach, biological predictors of treatment response 
may offer greater insight into the neurobiological substrates of the disorders and serve 
as potential targets for future interventions.  
Neuroimaging predictors of treatment response: Depression 
 
 The majority of work identifying neuroimaging predictors of treatment 
response has been done in Major Depressive Disorder (MDD) after Mayberg and 
colleagues (1997) discovered that pre-treatment pregenual anterior cingulate glucose 
metabolism could differentiate responders from non-responders to antidepressant 
medication response. Following this finding, subsequent studies have replicated this 
effect using positron emission tomography (PET) as well as functional magnetic 
resonance imaging (fMRI) across a variety of tasks (Chen et al., 2007; Langenecker 
et al., 2007; Saxena et al., 2003; Victor, Furey, Fromm, Ohman, & Drevets, 2013).  
Similarly, studies examining ventral anterior cingulate have found greater activation 
corresponds to better antidepressant treatment response (Brockmann, et al., 2009; 
Keedwell et al., 2010). Moreover, a recent meta-analysis found that in nineteen out of 
twenty-three studies, including resting and task-based designs, responders to various 
antidepressant treatments (medication, ECT, rTMS) had increased pre-treatment 
rostral/ventral ACC activity which was found consistently across treatments (SSRIs, 




fMRI, and SPECT), and did not depend on medication status at baseline (Pizzagalli, 
2010).  
 While the majority of work on predictors of depression treatment response has 
been done in pharmacological studies, research employing Cognitive Behavioral 
Therapy (CBT) as the intervention have typically found less pretreatment ACC and 
prefrontal cortex activation predicts better treatment outcome (Dichter, Felder, & 
Smoski, 2010; McGrath et al., 2014; Siegle et al., 2006, 2012). In this regard, it has 
been suggested that in depressed samples ACC activity may optimize treatment 
selection, such that individuals with lower pre-treatment ACC may respond better to 
CBT, while individuals with greater pre-treatment ACC may respond better to 
antidepressants.  
Interestingly, the majority of depression treatment prediction research has 
been conducted using fMRI or PET modalities, with limited evidence employing 
electroencephalography (EEG). While task-based (event related potential) predictors 
of treatment response is sparse, resting-state EEG evidence is consistent with the 
neuroimaging literature and suggests increased frontal-midline theta with neural 
generators in the anterior cingulate (ACC) may predict favorable treatment outcome 
(Mulert et al., 2007; Pizzagalli, et al., 2001, Pizzagalli et al., 2003; Spronk et al., 
2011). However, more research is needed to determine if this effect extends to event 
related potentials.  
 While the ACC has been the most consistent and robust predictor of 
antidepressant treatment outcome, it is important to point out that other regions have 




across studies. In some studies using emotional processing tasks, greater prefrontal 
activity (dorsolateral and dorsomedial PFC) is associated with better outcomes to 
both medication and CBT (Ritchey et al., 2011; Samson et al., 2011). However, other 
studies using working memory tasks suggest less PFC activation is associated with 
better response (Walsh, et al., 2007). The amygdala, insula, hippocampus, and 
orbitofrontal cortex (OFC) have also been studied as predictors of treatment response, 
but have similarly generated mixed findings.  
In summary, pre-treatment ACC activity has been shown to consistently 
predict treatment outcome in major depression, and may potentially be used to 
optimize treatment selection by differentiating between medication and 
psychotherapy response. 
Neuroimaging predictors of treatment response: Anxiety 
 
Because depression is often comorbid with anxiety, we might expect to see 
similar results for predicting anxiety treatment response. Even though research in this 
area is just beginning, emerging evidence shows a similar effect, indicating the ACC 
is the most consistent predictor for anxiety treatment outcomes as well. According to 
two review papers on neuroimaging predictors of treatment response in anxious 
populations, similar to the findings in depression, anxious patients with enhanced pre-
treatment anterior cingulate activity generally have greater response to a variety of 
interventions (Ball, Stein, & Paulus, 2014; Shin et al., 2013).  
In contrast to depression, anxiety psychopathology represents a heterogeneous 
group of disorders, which have traditionally included Generalized Anxiety Disorder 




Disorder (OCD), and Posttraumatic stress disorder (PTSD). Of all the anxiety 
disorders, the most neuroimaging treatment prediction work has been done in OCD. 
Within this patient group, studies have consistently implicated the cingulate cortex 
(including anterior and posterior) and orbital frontal cortex (OFC), with a majority 
showing greater pretreatment activation in ventral anterior cingulate and posterior 
cingulate is associated with better medication response rates (Buchsbaum et al., 2006; 
Rauch et al., 2001; Rauch et al., 2002) as well as better response to an 
electrostimulation intervention (Van Laere et al., 2006). In contrast to the ventral 
ACC findings, some studies have found an inverse relationship between dorsal ACC 
and OCD treatment response, such that lower pre-treatment dorsal/caudal ACC 
predicts better response (Hendler et al., 2003; Swedo et al., 1989). Interestingly, there 
is a lack of studies assessing whether the same anterior and posterior cingulate 
predictors apply to cognitive behavioral therapy for OCD. As a result, although the 
majority of findings on treatment prediction in OCD suggest a role for the ACC, it is 
currently not clear whether this extends to psychotherapy, or whether subdivisions of 
the ACC may show different predictive directions in this population.  
Additionally, much less work has been done examining predictors of 
treatment response in the other anxiety disorders. Of the few studies that have been 
conducted, the two regions of interest have been the ACC and the amygdala. While 
the amygdala has been robustly associated with fear based anxiety disorders (Davis, 
1992) and is hyperactive broadly across anxious phenotypes (Etkin & Wagner, 2007), 
its role in predicting treatment response is less clear.  In fact, several studies found no 




2013; Evans et al., 2009; Nitschke et al., 2009). In contrast to mostly null prediction 
findings in the amygdala, greater dorsal ACC has been consistently found to predict 
better CBT response in individuals with PTSD (Aupperle et al., 2013; Bryant et al., 
2018), as well as social anxiety (Klumpp, Fitzgerald, & Phan, 2013), and better 
medication response in GAD (Nitschke et al., 2009). Ventral ACC has also shown 
predictive value, but the direction of prediction has been less consistent across types 
of interventions and disorders. In medication studies, for example, greater ventral 
ACC predicted better response in GAD (Whalen et al., 2008), but lower ventral ACC 
predicted better response in social anxiety disorder (Evans et al., 2009).  
Regarding mechanisms of treatment prediction, several studies speculate that 
increased ACC may represent an adaptive response by calling upon cognitive control 
resources primarily located in dorsolateral PFC (Cavanagh, Cohen, & Allen, 2009; 
Cavanagh & Shackman, 2015; Miller & Cohen, 2001; Pizzagalli, 2010). The extent to 
which these two regions (and others) are integrated in processing various cognitive or 
affective challenges is considered an index of their functional connectivity. The 
functional connectivity (or synchronization) between regions can be assessed across a 
number of tasks, including during cognitive control (Cavanagh et al., 2009), 
perception of human faces (Rodriguez et al., 1999), working memory (Bluhm et al., 
2011), and complex attention (Rosenberg et al., 2016). Functional connectivity can 
also be assessed by a number of imaging modalities, including EEG. Specifically, 
inter-channel phase synchrony between medial to lateral prefrontal regions has been 
shown during gambling feedback tasks (Watts et al., 2017), as well as during go/no-




2013). Moreover, disrupted synchronization has been implicated in a variety of 
pathological conditions, including schizophrenia, epilepsy, autism, Alzheimer’s, and 
Parkinson’s (Uhlhaas & Singer, 2006).   
Given the role for functional connectivity in understanding basic task 
processing, as well as its implication in pathological brain states, it may also be 
informative for predicting clinical treatment outcomes. Indeed, there is some evidence 
suggesting a role for dorsolateral PFC, in addition to ACC, as a predictor of treatment 
response in individuals with GAD and panic disorder (Ball, Stein, Ramsawh, 
Campbell-Sills, & Paulus, 2014), as well as OCD symptom reduction (Olatunji et al., 
2014). Importantly however, these studies did not examine the functional relationship 
between ACC and DLPFC. In fact, very few studies have assessed functional 
connectivity between these regions as treatment predictors, despite several studies 
speculating that regulatory capacity or cognitive control capability may be a 
mechanism underlying treatment prediction findings. To our knowledge there has 
been only one study to examine ACC/DLPFC functional connectivity as a predictor 
of treatment outcomes. This study was conducted by Klumpp and colleagues (2016), 
hereafter referred to as ‘the Klumpp study.’ This study used fMRI to examine both 
the activation and functional connectivity between ACC and PFC in relation to 
treatment outcomes. Results indicate greater anxiety treatment response to CBT was 
predicted by more dorsal ACC activity and lower functional connectivity between 
dACC and DLPFC to negative stimuli during high cognitive demand (Klumpp et al., 
2016). Based on these findings, the authors concluded that patients with overall less 




promising, more research is needed on the functional connectivity between ACC and 
DLPFC in relation to predicting treatment response.  
Additionally, it’s important to point out that the vast majority of treatment 
prediction work has been done using fMRI or PET paradigms, with very few studies 
examining EEG predictors. Of those studies using EEG, the early prediction work 
focused broadly on alpha or theta frequencies during sleep and resting state. While 
one study indicated resting EEG alpha asymmetry predicts better anxiety treatment 
response to Cognitive Behavioral Therapy (Moscovitch et al., 2011), other studies 
found greater resting frontal midline theta predicted better medication response 
(Pizzagalli, et al., 2001; Spronk et al., 2011). Only more recent work has begun to 
examine ERPs as potential predictors of treatment response. Of those studies, there is 
some evidence to suggest lower time-domain Reward Positivity (RewP; 200-250ms 
following reward feedback) predicts better treatment outcome to CBT in a sample 
with comorbid anxiety and depression (Burkhouse et al., 2016). Another study found 
larger pre-treatment late positive potential (LPP; 400-1000ms) to aversive pictures 
predicted better treatment outcomes to CBT, also in individuals with anxiety and 
depression (Stange et al., 2017). While informative, future EEG research would 
benefit from building upon the existing body of neuroimaging findings by directly 
focusing on medial and lateral prefrontal regions in treatment prediction.  
In summary, examining predictors of treatment response in anxiety is an 
emerging field with relatively fewer studies compared to depression. Of the existing 
studies, converging evidence suggests greater dorsal ACC consistently predicts better 




functional connectivity to DLPFC) and the direction of the effect may depend on the 
type of anxiety disorder (i.e., less activation for OCD, but greater activation for all 
other anxiety disorders). Moreover, a majority of previous work has been limited to 
fMRI or PET paradigms. While not surprising given the use of these methods during 
the inception of treatment prediction work, EEG may serve as a quicker and more 
cost effective method with potentially greater applicability in clinical/hospital 
settings. As such, more work is needed to clarify and expand upon the role of the 
ACC in anxiety treatment response.  
Anterior Cingulate Cortex (ACC) 
 
Given its relevance to treatment prediction, it is important to clarify the 
structure and function of the ACC, as well as why activation in this region may be 
adaptive. Regarding structure, the anterior cingulate cortex is located in the medial 
wall of each hemisphere, adjacent to the corpus callosum, and can be functionally 
divided into two distinct regions: the ventral or rostral anterior cingulate cortex 
(rACC) and the dorsal or medial cingulate cortex (MCC). Anatomical studies suggest 
further delineation of both the rACC and MCC, resulting in four sub-regions 
(Palomero-Gallagher et al., 2008; 2009; Stevens, Hurley, & Taber, 2011). These 
studies suggest the rACC can be divided into pregenual anterior cingulate (pACC) 
and subgenual anterior cingulate (sACC) with each involved in different but 
overlapping functions. Similarly, the MCC can be further divided into anterior 
(aMCC) and posterior (pMCC) regions, resulting in a total of four main subdivisions 




indicated the main reason for separating the ventral/anterior and dorsal/middle 
regions of the anterior cingulate is the evidence pointing to different structural and 
functional connections (Vogt, 2009). To summarize, the MCC has extensive 
structural connections to lateral prefrontal, motor, and thalamic nuclei, and has been 
primarily implicated in ‘cognitive’ functions, including conflict-monitoring, 
response-selection, and execution. In contrast, the rACC has been associated with 
‘affective/emotional’ processing, as well as memory and reward-related functions, 
with primary connections to the amygdala, hippocampus, orbitofrontal cortex, and 
ventral striatum. Additionally, within the rACC, the pACC and sACC subdivisions 
have also shown evidence for differentiation such that pACC has more widespread 
connections to lateral prefrontal cortex and is functionally tied to emotion regulation, 
autonomic integration, and affect related to pain (Stevens, Hurley, & Taber, 2011). 
Compared to pACC, sACC has more connections to amygdala and ventral striatum, 
and is related to autonomic processes and conditioned learning (Haber & Knutson, 
2007; Ghashghaei, Hilgetag, & Barbas, 2007).  Similar differentiations occur within 
the MCC, such that aMCC is implicated in approach-avoidance decisions, conflict-
monitoring, control of actions, and emotional appraisal, whereas pMCC has more 
connections to inferior parietal cortex, and is functionally related to body-orientation 
and movement-execution.  
Despite previous evidence for different regions associated with cognitive and 
affective functions in the anterior cingulate, there is a growing consensus that the 
aMCC plays a unique role in the brain, with functional and structural connections to 




Shackman, 2015; Etkin et al., 2011; Pereira et al., 2010; Pessoa, 2008; Shackman et 
al., 2011). A meta-analysis performed across 192 studies and nearly 3,000 
participants demonstrates that negative affect, pain, and cognitive control are 
anatomically and functionally integrated in the aMCC (Shackman et al., 2011). In 
these studies, negative affect was indicated by tasks that induced negative emotions 
such as fear, anger and disgust, while pain represented tasks delivering physically 
painful stimuli such as heat, cold, or shock. The cognitive domain included tasks that 
induced reallocation of attention or execution of actions such as a Go/No-go or 
Flanker task. In the meta-analysis, functional segregation between ventral ACC 
(‘emotional’) and dorsal MCC (‘cognitive’) was tested after identifying voxels within 
these regions corresponding to negative affect, pain, and cognitive control. Consistent 
with previous work, results indicated studies of cognitive control elicited greater 
activation in MCC compared to rACC. However, negative affect was equally likely to 
activate the MCC and rACC, and studies of pain were more likely to activate MCC 
compared to rACC. Contrary to earlier notions that cognitive and emotional processes 
are differentially represented in the anterior cingulate cortex, these functional data 
suggest all three domains converge in the aMCC. Anatomical evidence also reviewed 
in this meta-analysis supports this notion by demonstrating the aMCC has substantial 
connections to subcortical regions involved in affect and pain (e.g., periaqueductal 
gray, amygdala, ventral striatum), as well as with frontoparietal regions implicated in 
cognitive control. Given these findings, the authors claim the aMCC may represent a 
hub that synthesizes information about pain, punishment or otherwise negative 




recruit other areas of the brain to modulate behavior. This theory is labeled The 
Adaptive Control Hypothesis (TACH) and claims that greater activation in aMCC 
serves an adaptive function by calling upon other regions to modulate behavior in a 
goal-directed manner (e.g., subcortical and cortical motor centers, amygdala, and 
prefrontal cortex). This theory may partially explain why greater ACC activation has 
been related to better treatment outcomes. 
 
Figure 1 (A) The human cingulate cortex can be divided into four major sections, including 
the subgenual anterior (blue), pregenual anterior (yellow), anterior midcingulate (green), and 
poster midcingulate (red). The anterior and posterior midcingulate are considered anatomical 
divisions of the dorsal midcingulate (MCC) which has been implicated in ‘cognitive’ 
functions, while the pregenual and subgenual anterior regions comprise the rostral or ventral 
cingulate (rACC) and have been tied to ‘emotional’ processes. (B) Despite previous evidence 
for the anatomical and functional divisions of the cingulate cortex, emerging research 
suggests the aMCC subdivision reflects both ‘cognitive’ and ‘affective’ processes, including 
greater activation during tasks associated with negative affect, pain, and cognitive control. 
Figure adapted from (Cavanagh & Shackman, 2015). 
 
ACC as reflected by Medial Frontal Theta 
 
An extensive body of literature has shown that activity in aMCC propagates to 
the scalp where it can be reliably measured by EEG and medial frontal ERPs at a 




Gehring & Willoughby, 2002; Hauser et al., 2014; Holroyd & Coles, 2002; Holroyd 
et al., 2004; Miltner, Braun, & Coles, 1997; Potts, Martin, Burton, & Montague, 
2006; Yeung, Botvinick, & Cohen, 2004). The three ERPs that have been consistently 
source localized to aMCC reflect feedback processing (Feedback Negativity, FN), 
error monitoring (Error Related Negativity, ERN), and response conflict (‘control’ 
N2). As a widely studied indicator of feedback and performance monitoring, the FN 
is a negative-going deflection which occurs approximately 250-400ms after 
performance/evaluative feedback (e.g., win or lose), and is typically more sensitive to 
negative versus positive feedback (Gehring & Willoughby, 2002; Miltner, Braun, & 
Coles, 1997). The ERN represents endogenous error monitoring (i.e., internal error 
signals) and is a negative-going ERP peaking approximately 50-100ms following 
erroneous responses (Falkenstein, Hohnsbein, Hoormann, & Blanke, 1991; Gehring, 
Goss, Coles, Meyer, & Donchin, 1993). Finally, the N2 is a negative deflection in the 
ERP waveform peaking approximately 250 to 350ms after the presentation of a 
stimulus eliciting the potential for response inhibition (Eimer, 1993; Folstein & Van 
Petten, 2008). All three medial frontal ERPs are negative deflections primarily 
represented in the theta frequency band and collectively have been designated medial 
frontal theta negativities (MFTN, ~4-8Hz; Cavanagh et al., 2009; Cavanagh et al., 
2012; Luu et al., 2004, 2003; Trujillo and Allen, 2007; Yordanova et al., 2004). 
While the neuronal sources for these components are not limited to just the aMCC 
(Bonini et al., 2014; Cohen et al., 2008; Emeric et al., 2010; Foti, Weinberg, Bernat, 
& Proudfit, 2014; Gehring & Willoughby, 2004), a number of studies using EEG 




implicated the aMCC as a key generator (Becker et al., 2014; Cohen et al., 2008; 
Gehring et al., 2012; Hauser et al., 2014; Wang et al,. 2005). 
Medial Frontal Theta Negativities (MFTN) and anxiety 
 
Extending this work to individual differences, Cavanagh & Shackman (2015) 
employed a series of meta-analyses, which showed MFTN (Theta-N2, Theta-FN, 
Theta-ERN) were not only reliable indicators of aMCC activity, but also correlated 
with greater dispositional anxiety and compensatory behavioral change. Specifically, 
all three medial frontal ERPs were enhanced (more negative) in relation to a number 
of self-report measures of anxiety (e.g., trait anxiety, behavioral inhibition, negative 
affect, general worry). Additionally, greater loss-related FN predicted greater 
avoidance of punishment on the subsequent trial, and greater ERN predicted slower 
reaction times following an error, consistent with the notion that aMCC, as indexed 
by medial frontal theta ERPs, contributes to the adaptive regulation of behavior.   
Error Related Negativity (ERN) 
The error-related negativity (ERN) is the medial frontal ERP that is most 
consistently associated with elevated levels of anxiety. Research has shown that the 
ERN is amplified in clinical populations, including individuals with obsessive-
compulsive disorder (Gehring, Himle, & Nisenson, 2000; Hajcak & Simons, 2002; 
Johannes et al., 2001; Mathews, Perez, Delucchi, & Mathalon, 2012; Ruchsow et al., 
2005) and generalized anxiety disorder (Weinberg, Klein, & Hajcak, 2012; Weinberg, 
Olvet, & Hajcak, 2010). In addition to diagnostic categories, transdiagnostic measures 
of anxiety also demonstrate a robust relationship with ERN (Hajcak, McDonald, & 




Yeung, 2013; Moser, Moran, & Jendrusina, 2012; Olvet & Hajcak, 2008). 
Interestingly however, different facets of anxiety (e.g., physiological arousal v. 
general worry) may show different sensitivities to the ERN amplitude. According to a 
meta-analysis conducted by Moser and colleagues (2013), studies utilizing continuous 
measures of anxious apprehension revealed a more robust relationship with the ERN 
(r = -0.35) than those using other measures of anxiety (r = -0.09). Specifically, results 
from one study indicated that anxious apprehension (i.e., general worry) but not 
anxious arousal (i.e., physiological symptoms of arousal) was associated with 
increased ERN amplitude (Moser, Moran, & Jendrusina, 2012). In these studies, 
‘anxious apprehension’ is defined as worry and verbal rumination in relation to 
perceived future threats, whereas ‘anxious arousal’ is defined as somatic tension and 
physiological hyperarousal elicited by clear and present threats. Making a similar 
distinction, previous research has also shown that the ERN is sensitive to trait but not 
state measures of anxiety (see Olvet & Hajcak, 2008 for a review), including anxiety 
sensitivity (Beste et al., 2013), and negative affect/emotionality (Hajcak, McDonald, 
& Simons, 2004; Luu, Collins, & Tucker, 2000). 
Taken together, medial frontal ERN is consistently enhanced in relation to 
anxiety disorders, particularly those with general worry symptoms. Importantly 
however, while the magnitude of the ERN has been shown to predict the longitudinal 
development of anxiety disorders in the subsequent three years (Meyer, Hajcak, 
Torpey-Newman, Kujawa, & Klein, 2015), it’s relation to predicting treatment 
response has not been assessed.  




Although not as well established as the ERN and anxiety, a similar 
relationship between the feedback negativity (FN) and anxiety is emerging. While the 
time-domain literature on FN and anxiety contains some mixed results, approximately 
half of the studies suggest medial frontal FN is enhanced in relation to anxiety. 
Specifically, across different feedback tasks, multiple studies found enhanced loss-
related FN for individuals with greater behavioral inhibition (DePascalis et al., 2010; 
Balconi & Crivelli, 2010), a trait common in many anxiety disorders. Additional 
research focusing on negative affect/emotionality, commonly seen in anxiety 
disorders, found enhanced FN amplitude and ACC activity for individuals with 
greater negative emotionality (Santesso et al., 2012; Sato et al., 2005). Enhanced FN 
was also found in the context of ambiguous feedback for individuals with greater 
dispositional anxiety (Gu, Ge, Jiang, & Luo, 2010). 
More importantly, several recent studies demonstrate a consistent link 
between enhanced frontal midline theta-FN and anxiety (Cavanagh & Shackman, 
2015; Ellis, Watts, Schmidt, & Bernat, 2018; Mueller et al., 2014; Mueller et al., 
2015; Osinsky et al., 2017). For example, Mueller and colleagues (2014) found 
increased frontal midline theta power for individuals with high neuroticism/anxiety. 
Additionally, among individuals with both depression and anxiety, enhanced 
processing of negative feedback was associated with greater medial frontal theta and 
aMCC activity (Mueller et al., 2015).  
To help contextualize these results, a recent paper by our group points out that 
discrepancies in the time-domain FN and anxiety literature may be due to the 




2018). Specifically, while frontal midline theta-FN was enhanced for individuals with 
greater anxiety, delta-FN (<4Hz) was also significantly modulated by anxiety. 
Regression results revealed that blunted or non-significant time-domain FN may be 
due to suppression effects occurring from an increased positive-going delta, 
combined with an increased negative-going theta. As such, research focusing on the 
spectral properties of FN is important for generating an accurate depiction of its 
modulation with respect to individual differences. However, despite the evidence for 
theta-FN as a marker of anxiety, no studies have examined this component as a 
predictor of anxiety treatment response. 
N2 
Compared to the ERN and FN, fewer studies have assessed the N2 in relation 
to anxiety. Nevertheless, the results from those studies are consistent with the 
previous two ERPs and suggest that medial frontal N2 is similarly enhanced in 
relation to various measures of anxiety. For example, Sehlmeyer and colleagues 
(2010) focused on anxiety personality traits in healthy undergraduate subjects and 
found evidence of enhanced no-go N2 amplitudes in individuals with greater trait 
anxiety. Using a different task and a smaller sample size, Righi and colleagues (2009) 
similarly found increased medial frontal N2 using trait and state measures of anxiety. 
Also within the context of anxiety traits, other research suggests behavioral inhibition 
is correlated with greater no-go N2 amplitudes over dorsal mid-cingulate (Armodio, 
Master, Yee, & Taylor, 2008). Finally, using a clinical population with obsessive 
compulsive disorder (OCD), Ruchsow and colleagues (2007) found that patients with 
OCD had enhanced (more negative) no-go N2 amplitudes compared to healthy 




not in medial frontal areas as expected. Similar to the ERN and FN, there is a lack of 
research on medial frontal theta-N2 as a predictor of anxiety treatment response, 
despite evidence for its association with anxiety and its neural correlates with aMCC.  
To summarize, medial frontal theta ERPs (i.e., ERN, FN, & N2) are 
consistently shown to reflect activity in aMCC, and are generally enhanced in relation 
to various measures of anxiety. However, while extensive evidence consistently 
implicates aMCC in treatment prediction work, medial frontal theta ERPs have not 
been evaluated as predictors of treatment response. Consistent with the emerging 
interest in treatment prediction for anxiety, examining these components represents a 
novel and important contribution to this area. As such, the primary aim of the 
proposed research is to evaluate medial frontal theta ERPs as predictors of anxiety 
sensitivity treatment response.  
Medial Frontal Theta Negativities as a shared process 
 
Given that all three medial frontal theta ERPs have been shown to reflect 
activity in aMCC, and all three have demonstrated a similar association with anxiety, 
it has been suggested that they may represent a “lingua franca” or a shared process in 
relation to motivationally significant outcomes (Cavanagh et al., 2012; Cavanagh & 
Shackman, 2015). In fact, Holroyd & colleagues (2008) suggest the FN is simply an 
N2 that occurs to unexpected negative feedback. This view is also supported by 
Cavanagh & colleagues (2012) who suggest N2 and FN may both represent a form of 
expectation mismatch, even though they are elicited under different cognitive 




drawn between the ERN and FN since both broadly reflect ‘performance monitoring,’ 
and according to the reinforcement learning theory, both are enhanced when the 
outcome is worse than expected (Holroyd & Coles, 2002). Additionally, evidence for 
performance monitoring and behavioral adjustment has been found for both ERPs. As 
a response-locked ERP, the ERN is most sensitive to errors of commission and has 
been linked to post-error slowing on subsequent trials, indicating an adjustment of 
performance. As a stimulus-locked ERP, the FN is most sensitive to negative 
feedback and is associated with post-punishment switching (for a meta-analytic 
review of ERN and FN behavioral change results, see Cavanagh & Shackman, 2015). 
Additionally, a number of studies point to the evidence from ERP source localization, 
fMRI, and simultaneous fMRI/EEG techniques which has suggested that all three 
components reflect activity in medial frontal regions including the anterior 
midcingulate cortex (aMCC; Cavanagh & Shackman, 2015; Gehring & Willoughby, 
2002; Hauser et al., 2014; Holroyd et al., 2004; Miltner, Braun, & Coles, 1997; Potts, 
Martin, Burton, & Montague, 2006).  
However, while the ERN and FN are both thought to reflect a performance 
monitoring system with primary activity over medial frontal regions, evidence for at 
least partially distinct processes underlying these components has been shown in 
terms of differing scalp distributions (Foti, Weinberg, Bernat, & Proudfit, 2014; 
Gehring & Willoughby, 2004) and differential sensitivity to externalizing 
psychopathology (Bernat, Nelson, Steele, Gehring, & Patrick, 2011), obsessive-
compulsive traits (Simons, 2010), and schizophrenia (Horan, Foti, Hajcak, Wynn, & 




circumstances, involve contributions from a diverse network of brain regions, and are 
differentially sensitive to some types of psychopathology, it has been suggested that 
these components reflect similar but distinct processes.  Given the two contrasting 
views, additional research is needed to clarify the convergent or discriminant nature 
of these ERPs in a variety of contexts. One area that has not been assessed is whether 
these ERPs represent shared versus independent contributions to predicting treatment 
outcomes.  
Summary and current aims  
As outlined in detail above, a large body of evidence indicates the most 
consistent predictor of treatment outcomes is activity in the anterior cingulate cortex 
(ACC). Although activity in ACC can be measured by medial frontal theta event 
related potentials (ERPs), these neurophysiological components have not been 
evaluated as predictors of treatment response. There is also a lack of research on the 
functional networks associated with ACC treatment prediction, despite implications 
for prefrontal engagement of cognitive control processes. Therefore, the present study 
aimed to examine these gaps in the literature by using task-based 
electroencephalography (EEG) and medial frontal theta negativities (MFTN) as 
predictors of anxiety sensitivity treatment response. 
Using amplitude as well as functional connectivity measures (i.e., inter-
channel phase synchrony) allows for insight into possible mechanisms. Moreover, by 
assessing multiple ERPs, this work contributes to the existing literature on whether 
these components represent a shared or unique medial frontal process.  




AIM 1: To assess the a) amplitude and b) inter-channel phase synchrony of MFTN 
(theta-FN, theta-N2) as predictors of anxiety sensitivity treatment response. 
Hypothesis: Increased medial frontal theta-FN and theta-N2 amplitude is expected to 
predict greater treatment response. With respect to phase synchrony, the directionality 
of effects could not be predicted based on limited work in this area. 
AIM 2: To determine if the MFTN components represent a shared or unique process 
in relation to treatment prediction.  
Hypothesis: Theta-FN and theta-N2 are expected to have shared variance in 
predicting treatment response.   
Significant impact: This work represents a novel contribution at the forefront of an 
emerging field, and may ultimately lead to the improvement in treatment efficacy and 





Chapter 2: Study Overview 
 
Using an archival dataset, medial frontal theta negativities were examined as 
predictors of anxiety sensitivity treatment response. As a brief overview, this dataset 
included approximately 275 individuals recruited from the community and was 
designed to assess cognitive and affective risk factors related to anxiety and suicide. 
Study duration for each participant was approximately 6 months, at the beginning of 
which each participant was randomly assigned to one of four treatment conditions.  
Throughout the study, participants completed a battery of self-report measures at 
multiple time points, and all subjects completed a baseline EEG assessment before 
undergoing treatment.  
Study design 
All participants completed a baseline assessment that included answering self-
report questionnaires related to anxiety and depression severity, as well as a baseline 
neurophysiological assessment that included EEG recordings during multiple tasks. 
Two of those tasks included gambling-feedback and go/no-go computer tasks, which 
were examined in the current study since those tasks elicited the medial frontal ERPs 
of interest.  
After the baseline assessment, participants were then randomly assigned to 
one of four conditions: Anxiety Risk Reduction (‘Anxiety-RR’), Depression Risk 
Reduction (‘Depression-RR’), Anxiety and Depression Risk Reduction (‘Combined-
RR’), or the repeated-contact control condition. All treatment groups (Anxiety-RR, 




only difference between groups was the type of stimuli that were shown in a subset of 
the intervention. Specifically, in the Anxiety-RR group individuals were presented 
with anxiety related stimuli in the Cognitive Bias Modification part of the treatment 
(described below), while the Depression-RR group was presented with depression-
related stimuli. The Combined-RR group represents a direct combination of the 
Anxiety and Depression intervention groups, such that participants received both 
anxiety and depression-related stimuli and therefore spent more time in the 
intervention per session. Regardless of intervention group, participants completed 
three intervention sessions at a rate of 1 session per week for three weeks (Figure 2). 
For the Anxiety-RR and Depression-RR groups, each session lasted approximately 1 
hour. For the Combined-RR group, sessions lasted approximately 1.5 hours due to the 
inclusion of both anxiety and depression-related intervention materials. Session 1 of 
treatment focused on psychoeducation and brief exposure therapy in the form of 
‘Cognitive Anxiety Sensitivity Treatment’ (CAST; described in more detail below). 
Session 2 and 3 incorporated Cognitive Bias Modification (CBM) for the majority of 
the session, and allowed a small portion of time for review of psychoeducational 
materials. In addition to the three treatment sessions, participants were instructed to 
practice the CAST exposure exercises (learned in session 1) daily as ‘homework’ 
until none of the exercises generated any fear/distress. 
The control group represented a repeated contact condition, where each 
participant was assigned a personal study coordinator and asked to check-in with that 
coordinator at various intervals. During each check-in, the coordinator asked about 




check-in occurred once per week over the phone and suicide risk was also evaluated. 
The purpose of the repeated contact design was to control for any effects of personal 
interaction that may mitigate anxiety and mood disorder symptoms, as well as to 
control for symptom improvement over time. This is an important component of the 
existing dataset because many clinical trials involving psychotherapy typically do not 
include a control condition, so it is unclear if predictors of treatment response 
identified in those studies are specific to the intervention or simply to symptom 
alleviation over time.  
 
Figure 2. Timeline of procedures for the Combined treatment (left) and 
control (right) groups. Note: * indicates the order of mood and anxiety 
components was counterbalanced across participants. 
 
In addition to the baseline assessment and the intervention procedures, the 
study design also incorporated post-treatment EEG sessions for a small subset of 
subjects randomly selected from the Combined-RR and Control groups (Combined-
RR N=25, Control N=25). These individuals underwent intensive neurophysiological 




included 1) mid-treatment (after session 2), 2) post-treatment (1 week post-treatment), 
and 3) 6 months post-treatment. Unfortunately however, due to attrition there were 
only 15 subjects with post-treatment data in the treatment group, and 14 subjects with 
post-treatment data in the control group. Given the low number of subjects in each 
group and the low power to detect a between group effect (Power=.08; two tailed 
independent samples t-test with estimated Cohen’s d=.2, alpha level=.05, Group 1 
N=15, Group2 N=14), the pre/post change in neurophysiological data was not 
analyzed.   
Additionally, unfortunately the ERN could not be assessed using this dataset 
due to the limited number of subjects with erroneous responses. Methodological 
studies demonstrate that at least six error trials/epochs are needed to reliably elicit an 
ERN (Olvet & Hajcak, 2009; Pontifex et al., 2010; Steele et al., 2016). In this dataset, 
only four subjects made 6 or more errors during the Go/No-go task, indicating this 
particular task cannot be used to assess the ERN. Three out of the other four tasks 
collected in this dataset did not involve response data (i.e., picture viewing and 
resting tasks), and therefore are not viable candidates for eliciting an ERN. The only 
other task in this dataset that elicits correct and incorrect responses is the three-
stimulus visual Oddball task. However, this task generated even fewer error counts, 
with only two subjects making six or more errors. As such, the existing dataset does 
not contain sufficient ERN data, and therefore the current analyses focus on the FN 






Chapter 3: Methods 
Participants 
 
A total of 275 subjects participated in the study at Florida State University that 
assessed neurophysiological markers and psychological risk factors related to anxiety 
and depression. Thirty-four participants were excluded due to an excessive number of 
EEG artifacts (>50% of trials rejected using methods described in Data 
Preprocessing), two participants did not have useable data due to equipment 
malfunctions while recording, and six subjects failed to complete the baseline self-
report measures. This left a total of 233 participants for analysis (129 females; M 
age= 35.03 years, SD= 15.91 years). All participants were 18 years of age or older 
and were screened for neurological conditions, visual impairments, and/or traumatic 
brain injuries.  
Eligibility for the study was based on an assessment of risk factors for anxiety 
and depression, as determined by elevated scores on the 18-item self-report Anxiety 
Sensitivity Index-3 (ASI-3; Taylor et al., 2007) or elevated scores on the 15-item self-
report Interpersonal Needs Questionnaire (INQ-15; Hill & Petit, 2013; Van Orden, 
Cukrowicz, Witte, & Joiner, 2012).  The ASI-3 measures an individual’s tendency to 
interpret anxiety-related sensations as potentially harmful or fear inducing, and has 
been shown to be a risk factor associated with development of anxiety disorders and 
suicidal behavior (Taylor, Koch, & McNally, 1992; Schmidt, Zvolensky, & Maner, 
2006).  The INQ-15 assesses an individual’s level of perceived burdensomeness and 




development of mood disorders and suicidal behavior (Baumeister & Leary, 1995). 
To have continuous measures of anxiety severity across a range of anxiety disorder 
categories, the inclusion criteria was purposefully inclusive of those with and without 
a diagnosis. Individuals were excluded from participation if they met any of the 
following criteria: significant medical illness, current substance dependence, current 
or past psychotic spectrum disorder, uncontrollable bipolar disorder, or serious 
suicidal intent. Participants were provided informed consent before starting the study. 
Upon entering the study, all participants were assessed for psychiatric 
diagnoses as determined using the Structured Clinical Interview for DSM-V, 
Research Version (SCID-5-RV; First, Williams, Karg, & Spitzer, 2015). The SCID-5-
RV was administered by trained doctoral level therapists with substantial training in 
SCID-5-RV administration and scoring. All SCID-5-RV results were reviewed by a 
licensed clinical psychologist to ensure accurate diagnoses. Previous studies 
conducted using this method of training and scoring have demonstrated high inter-
rater reliability (e.g., over 80% with a kappa of .77; Timpano & Schmidt, 2012).  
Intervention procedures 
 
The three treatment groups received a computer-based intervention that 
combined psychoeducation, brief exposure therapy in the form of Cognitive Anxiety 
Sensitivity Treatment (CAST), and Cognitive Bias Modification-Interpretation 
(CBM-I). The psychoeducation component lasted approximately 45 minutes in the 
first session and focused on the nature of stress and its effect on the body. Participants 




them and were instructed to participate in guided exercises to correct the fear 
response associated with bodily sensations. The guided exercises took the form of a 
brief exposure therapy, labeled CAST. CAST was developed based on educational 
and behavioral techniques commonly employed in the treatment of individuals with 
anxiety disorders and was adapted from a similar intervention used by Schmidt and 
colleagues (2007). CAST was specifically designed to reduce anxiety sensitivity (AS) 
symptoms, which are associated with the etiology and maintenance of multiple types 
of psychopathology. Additionally, proof of concept effects in ongoing pilot studies 
suggest immediate post-intervention anxiety reduction, as measured by the ASI-3. 
During the CAST portion of the session, participants were first directed to complete a 
standardized assessment of their fear to different arousal sensations. With the 
program’s direction and assistance, participants completed repeated exposure trials of 
engaging in an arousing sensation (i.e., hyperventilation) followed by rating the level 
of arousal they experienced during the exercise (scale of 1 to 10, with 10 being the 
highest). They were told that they would repeat each exercise until their subjective 
rating of distress was rated as minimal (0-1). They were also instructed to complete 
one set of each of the exercises daily until none of the exercises generated any 
fear/distress.  
As the third component of the intervention, CBM-I focuses on changing an 
individual’s automatic interpretation of incoming information. This was done by 
providing feedback to participants about whether their interpretation of stimuli was 
correct. During the task, participants were presented with a word (e.g., “excited”) for 




beating faster”). They were then asked to determine if the word was related to the 
sentence by pressing “yes” if they thought they were related, and “no” if they thought 
they were not related. On half of the trials, the combination of word and sentence 
created a benign meaning (previous example), while the other half of trials created an 
anxious meaning (e.g., “stressful” followed by “Your mind is full of thoughts”). 
Participants were given feedback during training such that “correct” feedback was 
elicited by judging the anxious combinations to be “unrelated” and the benign 
combinations to be “related”. If they judged the anxious combinations to be related 
and the benign combinations to be unrelated, they were given feedback that the 
response is “incorrect” and they heard a horn blast (approximately 85 decibels). An 
interpretation bias is typically measured by the number of trials in which participants 
endorse benign relationships and reject anxious or depressed combinations. 
Participants completed 40 test trials with no reinforcement (incorrect or correct 
feedback), followed by 80 training trials in which each response was given 
feedback/reinforced. Participants then took a short 5-minute break during which they 
completed a filler task (simple math problems), followed by another 80 training trials. 
At the end, they were given 40 test trials of novel words and sentences that they had 
not seen before. Unfortunately, response data were not collected in this dataset, so the 
effectiveness of each individual component of the treatment (CBM-I v. CAST v. 
psychoeducation) is unknown. However, the cumulative effectiveness of the 
intervention can be measured by examining change in symptom severity compared to 





Measures and tasks 
 
The primary treatment outcome measure was the Anxiety Sensitivity Index 
(ASI-3; Taylor et al., 2007), which is an 18-item self-report measure designed to 
assess an individual’s tendency to interpret anxiety-related sensations as potentially 
harmful or dangerous. These sensations may take the form of thoughts/cognitions, 
physiological experiences, or social situations. Example items include: “When I have 
trouble thinking clearly, I worry that there is something wrong with me” (cognitive), 
“It scares me when my heart beats rapidly” (physical), and “It is important for me not 
to appear nervous” (social). Respondents use a 5-point Likert-type scale ranging from 
0 (very little) to 4 (very much) to indicate the extent to which each item reflects their 
typical experience. Early work investigating AS demonstrated contributions to the 
etiology and maintenance of panic disorder (PD; Schmidt, Lerew, & Jackson, 1997; 
1999). Recently, AS has also been implicated in the development of several other 
affective disorders (Schmidt, Zvolensky, & Maner, 2006), including depression and 
generalized anxiety disorder (Allan, Capron, Raines, & Schmidt, 2014), obsessive-
compulsive disorder (OCD; Raines, Oglesby, Capron, & Schmidt, 2014), 
posttraumatic stress disorder (PTSD; Lang, Kennedy, & Stein, 2002), substance use 
disorders (McCaul, Hutton, Stephens, Xu, & Wand, 2017; Paulus, Hogan, & 
Zvolensky, 2018), and externalizing disorders (Bilgic et al., 2017). Further, empirical 
evidence suggests AS can be treated through brief interventions, ultimately resulting 
in reduced symptom severity across psychopathologies (Schmidt et al., 2007; 
Schmidt, Capron, Raines, & Allan, 2014; Smits et al., 2008). There has also been 




severity. Results from these fMRI studies show a positive association between self-
reported AS and activity in the insula and ACC during emotional processing tasks 
(Poletti et al., 2015; Stein et al., 2007).  
Participants also completed the 16-item Penn State Worry Questionnaire 
(PSWQ; Meyer, Miller, Metzger, & Borkovec, 1990), as well as the Beck Depression 
Inventory-II (BDI-II; Beck, Steer, & Brown, 1996). The PSWQ is a self-report 
measure designed to assess trait worry and apprehension using a Likert scale ranging 
from 1 (not at all typical of me) to 5 (very typical of me). It is a widely used tool for 
assessing Generalized Anxiety Disorder specifically, and has been shown to have high 
internal consistency and test-retest reliability. Total scores can range from 16 to 80 
with higher scores indicating greater severity. The BDI-II is another widely used self-
report measure for depression symptom severity. This measure includes 21 items 
scored from 0 to 3 where higher numbers indicate greater severity and/or frequency. 
All items are summed to generate a total score with higher scores indicative of greater 
depression symptom severity. 
 Participants also completed a series of tasks designed to assess cognitive and 
affective processes (e.g., emotional picture viewing tasks, visual oddball task, 
gambling feedback, go/no-go, resting state). The current analyses focused on the 
gambling and go/no-go tasks since these are reliably used in generating the FN 
(gambling feedback) and N2 (go/no-go) ERPs.  
The gambling task was a modified version used by Gehring and Willoughby 
(2002) in which the participant chose between two monetary options on each trial and 




money on that trial (Figure 3). Target stimuli consisted of two squares side-by-side, 
each containing a number (5 or 25) representing a monetary value (in cents). After 
subjects made a choice by pressing the left or right button, feedback was presented 
1000 ms after the button press. The feedback stimulus indicated the outcome of the 
participant’s decision. That is, the chosen box turned either red or green to signify 
either a win or a loss (with red or green as the winning color counterbalanced across 
participants), and the box that was not chosen turned the other color (either green or 
red) to indicate what the outcome of the trial would have been had that box been 
chosen. The feedback stimulus appeared for 1000 ms, followed by a blank screen for 
1500 ms preceding the onset of the next trial. Based on the design used by Gehring 
and Willoughby (2002), all four possible combinations of 5 and 25 (i.e., 5-5, 5-25, 
25-5, and 25-25) were evenly crossed with the four possible win/loss outcomes (win-
win, win-loss, loss-win, loss-loss), resulting in 16 trial types. Stimulus combinations 
and win/loss feedback on all trials were randomly determined, such that future trials 
were not predictable from outcomes associated with prior choices. Two sets of these 
16 trial types, ordered randomly, were included in each block. Upon completion of a 
block, participants received feedback about their win/loss ratio within that block. 





Figure 3.  Sequence of stimuli and feedback events in the gambling task. 
 
The Go/No-go task is a stimulus-response selection task where participants 
decide whether to execute or inhibit a response (Figure 4). Participants were 
presented with two different white letters (e.g., S-F) displayed sequentially on a black 
background, and instructed to press the right or left button corresponding to the letter 
that appeared (go trials; e.g., S=left, F=right). However, when the stimulus repeated 
itself participants were asked to withhold their response (no-go trials; e.g., the third 
letter in the string S-F-F-S-F). No-go trials were pseudo-randomly interspersed 
throughout the task such that one, three, or five go trials always preceded a no-go 
trial. Seven blocks of twenty-four trials each were completed, with eighteen go trials 
(75%) and six no-go trials (25%) in each block. Stimulus duration was 296 ms, the 
response window was 1150 ms, and the inter-trial-interval was 900 ms. Participants 
also completed a practice version of the task consisting of 20 practice trials with 
different letters, but no electrophysiology data was recorded during the practice. 























associations between the letter (e.g., S or F) and right/left button presses were 
counterbalanced across participants.  
 
Figure 4. Sequence and timing of events in the Go/No-go task. 
Psychophysiological data acquisition & processing 
 
All neurophysiological data was collected in a dimly lit sound attenuated 
room, where E-prime version 2.0 was used to present the computer tasks. 
Experimental stimuli was presented on a 21-inch Dell high definition CRT color 
monitor, centrally placed in front of participants at a viewing distance of 100 cm. 
Neurophysiological data was recorded using a BrainVision 96-channel 
actiCap (sintered Ag-Ag/Cl; international 10-20 system) as well as a 24-bit battery-
supplied active channel amplifier. Horizontal electrooculogram activity was recorded 
from electrodes placed on the outer canthus of both eyes, while vertical 




left eye. Impedances were kept below 10 kΩ. EEG signals were vertex referenced 
during recording, and referenced to average mastoid signals offline (electrodes TP9 
and TP10). Recordings were collected using a 500Hz sampling rate, analog 0.05 to 
100Hz bandpass filter, and digitized at 1000 Hz using BrainVision PyCorder (Brain 
Vision LLC). 
Epochs of three seconds were taken from 1000 ms pre to 2000 ms post 
stimulus with a 150 ms to 10 ms pre-stimulus baseline, and re-referenced to averaged 
mastoid sites. Data was corrected for ocular artifacts using an algorithm developed by 
Semlitsch and colleagues (1986) in the Neuroscan Edit 4.5 software (Neuroscan, 
Inc.), and downsampled to 128 Hz using the Matlab resample function (Mathworks, 
Inc.), which applies an anti-aliasing filter during resampling. Then, two methods of 
data cleaning were used. In the first method, trials were rejected if activity at frontal 
electrodes (F3 or F4) exceeded ±100 µV in either the pre-stimulus period of -1000 to 
-1 ms, or the post stimulus period of 1 to 2000ms. Within-trial individual electrodes 
were rejected if activity exceeded ±100 µV during the same pre- and post-stimulus 
time periods. This removed 14.9% of all trials from the gambling task, and 13.8% of 
all trials from the Go/No-go task. Additionally, visual analysis of the averaged 
waveforms indicated that 94 electrodes out of 25,850 (0.4%) were disconnected 
during recording in the gambling task, and 135 (0.5%) were disconnected during 
recording in the Go/No-go task. These electrodes were replaced with the mean of the 
three nearest neighbors. After preprocessing, the data were averaged according to 







Time-frequency (TF) analysis is a technique that can be used to disentangle 
overlapping frequency band effects in several common ERP signals, including the FN 
and N2 components (Bernat, Williams, & Gehring, 2005; Bernat, Malone, Patrick, & 
Iacono, 2007; Bernat, Nelson, & Baskin-Sommers, 2015; Harper, Malone, & Bernat, 
2014). As suggested by previous work (Bernat et al., 2005), time-frequency principal 
components analysis (TF-PCA) can be used to parse overlapping spatial and temporal 
activity related to both ERP components. To separate theta activity relevant to each 
component, the data were pre-filtered using a 2 Hz high-pass and 7 Hz low-pass filter 
before applying the TF-PCA, to isolate theta-band activity. Next, the theta-filtered 
signals were transformed into time-frequency energy representations using the 
binomial reduced interference distribution (RID) variant of Cohen’s class of time-
frequency transforms. Generally, the binomial RID transformation computes a 
complex time-frequency distribution with uniform time- frequency resolution, 
avoiding the trade-off between time and frequency resolution inherent to other 
transforms, including wavelet analysis (Bernat et al., 2005). Although either 
transform can be applied, wavelets have non-uniform time-frequency resolution, 
producing reduced temporal resolution at low frequencies and reduced frequency 
resolution at high frequencies (for additional details, see Aviyente et al., 2011; Bernat 
et al., 2005). Since RID does not suffer from this trade-off, it is arguably the more 
desirable transform and was therefore employed here. Following this, PCA with 
Varimax rotation was applied to the TF transforms separately for theta-FN and theta-




feedback (for FN) and post-stimulus (for N2) time window.  The resolution of the 
time-frequency transforms was 32 bins/second in the time domain, and 2 bins/Hz in 
the frequency domain, consistent with previous reports using these approaches. 
Figure 5 displays the grand average TF-PCA decomposition for theta in the 
Gambling (left) and Go/No-go (right) tasks. For the Gambling task, two components 
were extracted based on the scree plot and ability to distinguish the FN component, 
where both PCs accounted for a total of 43.59% of the variance. The first principal 
component (PC1) occurred earlier in the N1/P2 window (approximately 100-200ms) 
and accounted for 30.85% of the variance, while PC2 occurred during the FN window 
(approximately 225-400ms) and accounted for 12.74% of the variance. The variance 
accounted for by the first two principal components (PCs) far exceeded that 
accounted for by the next PC (e.g., PC3= 6.52% and PC4= 5.79%), indicating that 
retention of two PCs was justifiable. Similarly for the Go/No-go task, two 
components were extracted using the same criteria, where both PCs accounted for 
51.47% of the variance. The first PC (PC1) occurred in the N1/P2 time window (100-
250ms) and accounted for 34.65% of the variance. The second PC (PC2) occurred 
during the N2 window (approximately 200-400ms), and accounted for 16.81% of the 
variance. Again, the variance accounted for by the first two PCs exceeded that 
accounted for by the next PC (e.g., PC3= 8.31% and PC4= 5.68%), indicating that 
two components were justifiable. PCs during the FN window (Gambling- PC2) and 
N2 window (Go/No-go- PC2) served as the primary variables of interest. Electrode 
FCZ was most proximal topographically to the center of activation for theta-FN 




Therefore, the average of three electrodes in medial frontal (FCZ, FC1, FC2) areas 
will be included in analyses. 
 
 
Figure 5. Grand average time-frequency (TF) decomposition of theta during the Gambling 
task (left) and the Go/No-go task (right) using principal components analysis (PCA) across all 
trial types (i.e., gain and loss trials in Gambling, & go and no-go trials in Go/No-go). 
Waveform plots, top level: Average time-domain ERPs across all trials, theta frequency-
filtered. Color surface plots, second level: grand average time-frequency effects, with 
principal components depicted beneath. Colored topographical head maps: scalp topography 
distributions for the mean of the respective principal components. Gambling theta effects are 
best captured by two principle components, where PC1 represents theta-N1/P2, and PC2 
represents theta-FN and is maximal at FCZ regions. Go/No-go theta effects are also indicated 
by two principal components, where PC1 represents N1/P2, while PC2 represents N2 and is 
maximal at FCZ regions.  
 
Time-frequency inter-channel phase synchrony (ICPS) 
 
Inter-channel phase synchrony (ICPS) indexes the degree of phase alignment 




connectivity between regions (Cavanagh et al., 2009; Cohen, 2011). Specifically in 
the theta band, ICPS between medial and lateral prefrontal regions has been widely 
studied in the context of tasks requiring cognitive and affective control. These studies 
show that during trials that elicit more surprise, conflict, or punishment, as well as 
those that are particularly valuable tend to show increased ICPS between the ACC 
and lateral prefrontal cortex, in addition to other brain regions (Aviyente et al., 2017; 
Bolanos, Bernat, He, & Aviyente, 2013; Hanslmayr et al., 2007; Luft, 2014; Smith et 
al., 2015; Watts, Tootell, Fix, Aviyente, & Bernat, 2018). Taken together with the 
treatment prediction work suggesting a role for regulatory ability and prefrontal 
control networks, medial frontal theta components will be assessed for phase 
synchrony with lateral prefrontal electrodes (Figure 6) over the FN and N2 windows. 
To avoid spurious phase synchrony between scalp electrodes due to volume 
conduction (Srinivasan et al., 2007), all EEG epochs will first be transformed using 
current source density (CSD), which minimizes volume conduction by source 
localizing activity toward the cortical surface (Tenke and Kayser, 2012). 
Subsequently, phase-synchrony will be computed as a phase locking value (PLV; 
Aviyente et al., 2011; Lachaux et al., 1999) which represents the average difference 
in phase-synchrony between a pair of electrodes across epochs. PLV values range 
from 0 to 1, where 1 indicates highly consistent phase synchrony between electrodes, 
and values near 0 indicate almost entirely unrelated phase between electrodes. As 
such, PLV will be used to quantify the synchrony between medial frontal and bilateral 
frontal theta EEG signals, separately for the FN and N2 windows. To do so, the mean 




PLVs).  The PLV values, representing phase synchrony between medial and lateral 
prefrontal regions, will be used to predict magnitude of treatment response at mid-
treatment, 1-week post treatment, and 6 months post treatment.  
 
Figure 6. Topographical representation of electrodes in the 96-channel EEG cap. Red 
indicates medial frontal (FCZ) and lateral frontal (F3 & F4) electrodes included in 
ICPS analyses for theta-FN and theta-N2.  
 
 
Data analytic methods 
Analyses of behavioral, demographic, and treatment outcome data are 
reported first, followed by analyses of neurophysiological data as predictors of 
treatment outcome. Amplitude and inter-channel phase synchrony for theta-FN and 
theta-N2 are separately assessed as pre-treatment predictors of anxiety sensitivity 
response. Treatment response was defined at three time points by the percent change 
in anxiety sensitivity symptoms on the ASI self-report measure.  
Primary treatment prediction analyses were conducted in two steps. Step 1 




to determine if any significant effects were present. The purpose of this first step was 
to reduce the number of bivariate comparisons and to represent an ‘omnibus’ model 
where all variables of interest were considered simultaneously. To do this, a treatment 
group by time by MFTN fixed effects linear mixed model (LMM) was performed on 
symptom severity (i.e., mean ASI scores).  
Linear Mixed Models were run separately for each neurophysiological 
predictor (theta-FN gain, theta-FN loss, theta-N2 go, theta-N2 no-go) for both 
amplitude and inter-channel phase synchrony, resulting in a total of 8 models. In all 
models, separate terms were included for each of the treatment groups and dummy 
coded relative to the control. For simplicity, groups were labeled as Group1 
(combined treatment), Group2 (anxiety treatment), and Group3 (depression 
treatment), with the intercept as the control group. The ‘time’ variable in each model 
included four levels, quantified as weeks into the study (i.e., baseline=0, mid-
treatment=2, 1-week post treatment=4, and 6 months post-treatment=26). The 
dependent variable in each model was the primary outcome measure (i.e., average 
anxiety sensitivity scores). Terms of interest within each model included the three 
Group x MFTN interactions (e.g., Group1 x Theta-FN gain amplitude; Group2 x 
Theta-FN gain amplitude; Group3 x Theta-FN gain amplitude), as well as the three 
Group x MFTN x Time interactions. Within each model, the two-way interactions 
tested whether the MFTN variable differentially predicts treatment response based on 
treatment group (e.g., does Theta-FN gain amplitude predict treatment response in 
any of the three treatment groups relative to the control?). The three-way interactions 




example, if a significant two-way interaction was identified, but the three-way 
interaction was non-significant, this would indicate that the treatment prediction 
effect did not differ as a function of time (i.e., it was consistent across time points). 
An unstructured covariance matrix with restricted maximum likelihood estimation 
was used. Due to the number of models being tested, Bonferroni p-value correction 
was applied such that significance in the models is based on p<.0125 (.05/4 for 
amplitude and .05/4 for ICPS).  
Step 2 of the analyses involved specific effects testing with the purpose of 
assessing the specificity, sensitivity, and incremental validity of any significant 
effects identified in step 1. To do this, significant interactions from the linear mixed 
models were further assessed with nonparametric spearman correlations. 
Nonparametric methods were used due to their robustness against violations of 
normality. Specificity is indicated here by effects that are present for one group and 
not the other/s. Sensitivity is demonstrated by reliability (i.e., consistency across 
time) and accuracy (i.e., percent of individuals classified as responders versus non-
responders). To test for incremental validity, partial spearman correlation coefficients 
are reported after controlling for baseline symptom severity, and other self-report 
measures (including anxiety and depression) that may be quicker and more cost-
effective predictors. Age and gender were also assessed in relation to treatment 
response. Multiple comparison correction was applied based on the number of 




Finally, theta-FN and theta-N2 were assessed for unique versus shared effects 
in relation to treatment outcome by entering both into a regression model predicting 
treatment response.  
Given the extensive literature showing enhanced ACC activity as a predictor 
of treatment outcomes, increased medial frontal theta-FN and theta-N2 amplitude is 
expected to predict greater treatment response. With respect to phase synchrony, the 
directionality of effects could not be predicted based on limited work in this area.  
For demographic purposes and to further illustrate treatment effectiveness, 
subjects will be characterized as achieving (1) a full response (≥50% improvement in 
ASI scores from baseline), (2) a partial response (<50% but ≥25% improvement), or 
(3) no response (<25% improvement), based on thresholds used in other treatment 
prediction studies (Nierenberg & DeCecco, 2001). Chi-square tests and Fisher’s 
Exact Tests will be used to compare response rates between treatment and control 
groups, and between ‘responders’ (≥50% improvement) versus ‘non-responders’ 










 Reaction times and accuracies were computed for the Go and No-go trial 
types. Correct responses to Go stimuli had a mean reaction time (RT) of 586.57 ms 
(SD= 138.93), and incorrect responses to No-go stimuli (false alarms) had a mean RT 
of 1969.08 ms (SD= 239.27). Mean accuracy rates for Go trials was 94.94% (SD= 
9.10), while the mean accuracy for No-go trials was 83.47% (SD= 14.58). The four 
treatment groups did not differ on mean RT to Go (p=.802) or No-go (p=.672). There 
were also no significant differences between groups on accuracy for Go trials 
(p=.355) or No-go trials (p=.708), indicating the four treatment groups did not differ 
in their behavioral performance. Reaction time and accuracy was not applicable in the 
gambling feedback task.  
Demographics & treatment efficacy 
 
Demographic characteristics for all four groups of subjects as well as their 
baseline severity scores (i.e., ASI) and response rates are shown in Table 1. The four 
groups do not significantly differ on age (p=.449), gender (p=.536), race (p=.292), or 
psychopathology (p=.356), indicating these factors were reasonably balanced across 
groups.  
Importantly, however, the treatment and control groups do show significant 
differences in response rates (Table 1, χ2 =29.13, df=6, p<.001). As shown in Figure 




improvement (M=63.77, SE=3.97), which was significantly greater than the anxiety 
group (M=45.43, SE=5.78; t=2.58, p=.011), the depression group (M=27.23, 
SE=6.46; t=4.82, p<.001), and the control group (M=15.50, SE=9.74; t=4.59, 
p<.001). The anxiety group had the second highest percent improvement, which was 
significantly greater than the depression group (t=2.1, p=.038) and the control group 
(t=2.7, p=.008).  The depression and control groups did not differ in treatment 
response magnitudes (t=1.0, p=.318).  
The combined treatment group also had a significantly greater proportion of 
individuals achieving full response (>50% improvement) compared to the control 
group (χ2 =13.85, p<.001). Specifically, 38 of 55 individuals (69.1%) in the treatment 
group achieved full response (Table 1), compared to 18 of 54 (33.3%) in the control 
group. Additionally, only 7 individuals in the combined treatment group (12.7%) 
experienced no response, while almost half of the control group (24/54; 44.4%) failed 
to show a response. This difference was also statistically significant (χ2 =13.34, 
p<.001), indicating the combined treatment was the most effective method of 












Table 1. Demographics and outcome indices for individuals in the treatment and  











Age (mean years, SD) 35.2(15.04) 34.2(16.76) 34.1(15.58) 36.7(16.49) 
Gender (N female) 29(48%) 37(62%) 32(56%) 31(55%) 
Race (N)  
 
white 37(61%) 38(63%) 35(61%) 31(55%) 
black 14(23%) 12(20%) 13(23%) 20(35%) 
other 9(15%) 10(17%) 9(16%) 5(9%) 
Psychopathology (N)     
 Anxiety disorders 20(33.3%) 29(48.3%) 19(33.3%) 24(42.8%) 
 Depressive disorders 13(21.7%) 12(20%) 16(28.1%) 9(16.1%) 
 Bipolar disorders 1(1.7%) 2(3.3%) 1(1.7%) 2(3.6%) 
 Trauma disorders 10(16.7%) 9(15%) 13(22.8%) 6(10.7%) 
 Obsessive compulsive disorders 2(3.3%) 2(3.3%) 1(1.7%) 4(7.1%) 
 Substance use disorders 4(6.7%) 0(0%) 1(1.7%) 1(1.8%) 
 Other (Axis II, somatic) 2(3.3%) 1(1.6%) 2(3.5%) 3(5.4%) 
 No diagnosis 8(13.3%) 5(8.3%) 4(7%) 7(12.5%) 
Baseline severity 
(mean ASI, SD) 
32.7 (16.8) 32.3 (17.4) 28.3 (16.0) 32.5 (17.7) 
Post-Treatment response rates  
 Responder (≥50% reduction) 38/55 (69.1%) 32/59 (54.2%) 16/54 (29.6%) 18/54 (33.3%) 
 
Partial Response (25-49% 
reduction) 
10/55 (18.2%) 17/59 (28.8%) 17/54 (31.5%) 12/54 (22.2%) 







Figure 7.  Post-treatment (1 week post) response rates according to 
intervention group. Individuals in the Combined-RR group had significantly 
greater improvement in anxiety sensitivity symptoms compared to all other 
groups. The Mood/Depression-RR group did not significantly differ from the 
control group.  
 
In addition to 1 week post-treatment, treatment effects are also apparent at the 
mid-treatment time point as well as 6 months post-treatment (Figure 8). As shown in 
Figure 8, the combined treatment group had significantly lower anxiety sensitivity 
scores at mid-treatment and 1-week post treatment compared to the control group 
(p’s<.001). This difference in symptom severity continued at trend level by 6 months 
post-treatment. Importantly, the groups did not differ in baseline severity, indicating 
the symptom reduction is not driven by pre-treatment severity differences. Overall, 
these results suggest the treatment is effective in reducing anxiety sensitivity 




group. Comparable to other interventions, approximately 30% of individuals did not 




Figure 8. Change in symptom severity over time between the control (blue) and 
Combined treatment (red) groups. Symptom severity was defined by mean scores on 
a continuous measure of anxiety sensitivity (AS). Improvement in symptoms is 
indicated here by a reduction in mean AS scores. Statistical comparisons indicate 
significant differences in symptom reduction between the control and treatment 
groups at mid-treatment and 1 week post-treatment, with a trend level difference at 6 




To demonstrate the gambling and go/no-go tasks reliably generate an FN and 
N2, the grand average for each component was assessed for basic condition 
differences. Consistent with previous findings, a one-sample t-test indicated the loss – 




11.27, p<.0001), indicating that the gambling task used in the present study reliably 
elicited an FN, and consistent with previous work, FN amplitude was maximal during 
processing monetary loss feedback compared to gain. Additionally, the loss-gain FN 
difference in theta was significantly greater than zero (M= .10, SD= .157; t= 10.02, 
p<.0001), consistent with previous work showing greater theta-FN amplitude to loss 
feedback compared to gain (Bernat et al., 2015; Bernat et al., 2011). Similarly for the 
N2, no-go – go differences in theta were significantly greater than zero (M= .05, 
SD=.08; t=9.45, p<.0001), consistent with previous work indicating theta-N2 is 
maximal for no-go compared to go stimuli (Harper et. al., 2014; 2016). These results 
demonstrate that the medial frontal theta ERPs of interest were reliably elicited in the 
gambling and go/no-go tasks, and sufficiently captured by time-frequency principal 
components analysis, justifying their use in further analyses.  
Predictors of treatment response: Step 1, Linear Mixed Models 
Using a comprehensive model with all four treatment groups and time points 
entered simultaneously, a series of Linear Mixed Models were conducted to 
determine if any significant effects were present. Terms of interest within each model 
include the three Group x MFTN interactions, as well as the three Group x MFTN x 
Time interactions. Within each model, the two-way interactions test whether the 
MFTN variable differentially predicts treatment response based on treatment group. 
The three-way interactions with time test whether this prediction effect differs as a 






Each of the theta amplitude variables (theta-FN gain, theta-FN loss, theta-N2 
go, theta-N2 no-go) were tested independently, resulting in four linear mixed models 
presented below. Groups are labeled as Group1 (combined treatment), Group2 
(anxiety treatment), and Group3 (depression treatment), with the intercept as the 
control group. The dependent variable in each model is the primary outcome measure 
(i.e., average anxiety sensitivity scores).  
  Model 1: Theta-FN Gain 
 Results from the first linear mixed model show a non-significant Group1 x 
Theta-FN Gain interaction on anxiety sensitivity severity (F=.378, df=283.41, 
p=.539), indicating that Theta-FN amplitude to gains did not differentiate the 
combined treatment and control groups on treatment response. Within the same 
model, there was a non-significant Group2 x Theta-FN Gain interaction (F=.852, 
df=282.12, p=.357), as well as a non-significant Group3 x Theta-FN Gain interaction 
(F=.196, df=284.15, p=.659). These results show that Theta-FN Gain amplitude did 
not predict treatment response in the combined, depression, or anxiety treatment 
groups relative to the control group.  
 These relationships were also tested in a three-way interaction with time in the 
model. All three tests were non-significant, including Group1 x Theta-FN Gain x 
Time (F=.093, df=418.03, p=.760), Group2 x Theta-FN Gain x Time (F=.671, 






Model 2: Theta-FN Loss 
 Similarly for Theta-FN Loss amplitude, there was a non-significant Group1 x 
Theta-FN Loss interaction on anxiety sensitivity severity (F=2.32, df=284.39, 
p=.128), as well as non-significant interactions for Group2 x Theta-FN Loss (F=.032, 
df=282.35, p=.858), and Group3 x Theta-FN Loss (F=.015, df=284.45, p=.901). 
These results indicate that Theta-FN Loss amplitude does not significantly predict 
treatment response to the combined, anxiety, or depression groups, relative to control.  
 These effects were also not modulated by time as shown by non-significant 
three-way interactions for Group1 x Theta-FN Loss x Time (F=.403, df=421.59, 
p=.526), as well as Group2 x Theta-FN Loss x Time (F=.011, df=410.56, p=.916), 
and Group3 x Theta-FN Loss x Time (F=2.51, df=421.90, p=.114).  
Model 3: Theta-N2 Go 
 Results indicate non-significant two-way interactions for Group1 x Theta-N2 
Go (F=1.48, df=270.74, p=.224), as well as Group2 x Theta-N2 Go (F=.114, 
df=270.17, p=.736), and Group3 x Theta-N2 Go (F=.593, df=270.23, p=.442). 
Similar to the above models, these results indicate that Theta-N2 Go amplitude does 
not significantly predict treatment response to the Combined, Anxiety, or Depression 
groups relative to control.  
 The three-way interactions with time were also non-significant for each of 
these terms, including Group1 x Theta-N2 Go x Time (F=.917, df=405.16, p=.339), 
Group2 x Theta-N2 Go x Time (F=.204, df=402.49, p=.652), and Group3 x Theta-N2 
Go x Time (F=.080, df=402.88, p=.777).  





Model 4: Theta-N2 No-go 
 Similarly for Theta-N2 No-go amplitude, results show a non-significant two-
way interaction for Group1 x Theta-N2 No-go (F=.278, df=270.15, p=.598), as well 
as Group2 x Theta-N2 No-go (F=.133, df=269.89, p=.715), and Group3 x Theta-N2 
No-go (F=.533, df=269.63, p=.466). These results show that Theta-N2 No-go 
amplitude does not significantly predict treatment response in the combined, anxiety, 
or depression groups, relative to the control.  
 These effects were also not modulated by time, as shown by non-significant 
three-way interactions for Group1 x Theta-N2 No-go x Time (F=.003, df=405.34, 
p=.955), as well as Group2 x Theta-N2 No-go x Time (F=.487, df=403.81, p=.486), 
and Group3 x Theta-N2 No-go x Time (F=.848, df=402.72, p=.358).  
 
 
Inter-channel Phase Synchrony (ICPS) 
 
Each of the theta ICPS variables (theta-FN gain, theta-FN loss, theta-N2 go, 
theta-N2 no-go) were tested independently, resulting in four linear mixed models 
presented below. Similar to the above models, groups are labeled as Group1 
(combined treatment), Group2 (anxiety treatment), and Group3 (depression 
treatment), with the intercept as the control group. The dependent variable in each 
model is the primary outcome measure (i.e., average anxiety sensitivity scores).  
Model 1: ICPS Theta-FN Gain 
 Results from the first model indicate a significant two-way interaction for 
Group1 x ICPS Theta-FN Gain (F=6.98, df=285.99, p=.009), indicating that Theta-




relative to the control. The three-way interaction for Group1 x ICPS Theta-FN Gain x 
Time was non-significant (F=2.07, df=425.92, p=.150), indicating that the above 
treatment prediction effect does not differ as a function of time.  
 The other treatment groups showed non-significant two-way interactions for 
Group2 x ICPS Theta-FN Gain (F=1.56, df=286.33, p=.213), as well as Group3 x 
ICPS Theta-FN Gain (F=2.71, df=290.29, p=.101), indicating that ICPS Theta-FN 
Gain does not predict treatment response to the anxiety or depression treatment 
groups relative to the control group. Finally, there were no significant three-way 
interactions for Group2 x ICPS Theta-FN Gain x Time (F=.006, df=417.34, p=.941) 
or Group3 x ICPS Theta-FN Gain x Time (F=2.09, df=466.19, p=.148).  
  Model 2: ICPS Theta-FN Loss 
 Similarly for ICPS Theta-FN Loss, there was a significant two-way 
interaction for Group1 x ICPS Theta-FN Loss on treatment response (F=10.82, 
df=286.39, p=.001), indicating that Theta-FN Loss phase synchrony predicts 
treatment response to the combined group relative to the control group. This effect 
was not modulated by time as shown by a non-significant three-way interaction 
between Group1 x ICPS Theta-FN Loss x Time (F=.165, df=413.88, p=.685).  
 ICPS Theta-FN Loss did not predict treatment response to the anxiety or 
depression groups relative to control, as shown by a non-significant Group2 x ICPS 
Theta-FN Loss (F=1.89, df=286.26, p=.170) and Group3 x ICPS Theta-FN Loss 
(F=3.29, df=291.39, p=.071) interactions. Three-way interactions for these terms 
were also non-significant (Group2 x ICPS Theta-FN Loss x Time: F=.916, 





  Model 3: ICPS Theta-N2 Go 
 Results show a significant Group1 x ICPS Theta-N2 Go interaction (F=12.37, 
df=279.47, p=.001), indicating that Theta-N2 Go phase synchrony significantly 
predicts treatment response to the combined group relative to the control. This effect 
was not modulated by time, as shown by a non-significant three-way interaction 
(Group1 x ICPS Theta-N2 Go x Time: F=.422, df=411.83, p=.516).  
 Similar to the previous models, ICPS Theta-N2 Go did not predict treatment 
response to the anxiety or depression groups relative to the control (Group2 x ICPS 
Theta-N2 Go: F=.319, df=278.93, p=.573; Group3 x ICPS Theta-N2 Go: F=.110, 
df=283.62, p=.741). The three-way interaction for these terms was also not significant 
(Group2 x ICPS Theta-N2 Go x Time: F=.036, df=409.91, p=.851; Group3 x ICPS 
Theta-N2 Go x Time: F=2.80, df=432.07, p=.095).  
Model 4: ICPS Theta-N2 No-go 
 Unlike the previous models, ICPS Theta-N2 No-go did not predict treatment 
response to the combined group (Group1 x ICPS Theta-N2 No-go: F=2.05, 
df=275.55, p=.153). It was also non-significant in predicting treatment response for 
the anxiety and depression groups relative to the control (Group2 x ICPS Theta-N2 
No-go: F=.001, df=275.22, p=.971; Group3 x ICPS Theta-N2 No-go: F=.378, 
df=278.81, p=.539). Finally, similar to the above models, the three-way interactions 
for these terms did not reach threshold for significance (Group1 x ICPS Theta-N2 
No-go x Time: F=.041, df=408.16, p=.840; Group2 x ICPS Theta-N2 No-go x Time: 
F=.868, df=407.15, p=.352; Group3 x ICPS Theta-N2 No-go x Time: F=4.69, 





Summary of Linear Mixed Model results 
 Medial frontal theta amplitude did not predict treatment outcomes for any of 
the treatment groups relative to the control. However, medial to lateral prefrontal 
phase synchrony for Theta-FN (Gains and losses) and Theta-N2 (Go’s) significantly 
predicted treatment outcomes for the combined treatment relative to the control 
group. Results suggest this effect is specific to the combined group and does not 
differ as a function of time. These three variables will be further analyzed for 
specificity, sensitivity, and incremental validity in step 2 reported below.  
 
Predictors of treatment response: Step 2, Correlations 
 
 Spearman correlation coefficients were computed for the three ICPS variables 
(Theta-FN gain, Theta-FN loss, Theta-N2 Go) and treatment groups (Combined 
treatment v. control group) that demonstrated a significant relationship to predicting 
treatment outcomes. Based on the number of tests, multiple comparison corrected was 
applied such that significance is based on p<.0055 (.05/9). As shown in Table 2, 
lower pre-treatment ICPS Theta-FN to gains is significantly correlated with better 
treatment outcomes. This effect was significant at the mid-treatment assessment 
(p=.001), as well as 1 week post-treatment (p=.003), and in a similar direction, 
though not significant, at 6 months post-treatment (p=.120). A similar finding 
occurred for ICPS Theta-N2 to Go stimuli, such that lower pre-treatment phase 
synchrony is correlated with better treatment response at mid-treatment (p=.001), and 
1 week post-treatment (p=.004), and is in a similar direction, though not significant, 6 




9 with the corresponding spearman rho effects. Finally, although lower ICPS Theta-
FN to loss was also associated with better treatment outcomes, the effect was only 
trend level at mid-treatment (p=.051), and did not reach significance 1 week post-
treatment (p=.134), or 6 months post-treatment (p=.265).  
Specificity of treatment prediction 
In contrast to the significant prediction effects for the combined treatment 
group, ICPS did not predict treatment outcomes to the control group (Table 2), thus 
demonstrating specificity of the treatment prediction effect. With the exception of 
ICPS Theta-FN to loss at trend level (p=.075), all other relationships did not approach 
significance in the control group (p>.10). 
 
Table 2. Spearman correlations for pre-treatment ICPS with treatment 
 response in the combined treatment group (top) and control (bottom). 
 Treatment response: Combined group 
Mid-tx 
(N=55) 
1 week post 
(N=49) 
6 mos post 
(N=39) 
ICPS Theta-FN 
Gain -.43*** -.41*** -.26 
Loss -.27
†
 -.22 -.18 
ICPS Theta-N2 Go -.44*** -.41*** -.19 
  
Treatment response: Control group 
Mid-tx 
(N=52) 
1 week post 
(N=47) 
6 mos post 
(N=34) 
ICPS Theta-FN 
Gain .22 .16 -.01 
Loss .25
†
 .11 .07 
ICPS Theta-N2 Go .01 .03 .03 







Figure 9. Scatterplots depicting relationships between pre-treatment phase synchrony for Theta-FN Gain and Theta-N2 Go 




Incremental validity: Examining potential covariates 
   
 Baseline symptom severity (i.e., mean ASI) as well as baseline depression and 
anxiety self-report measures were assessed as potential covariates. Baseline ASI 
significantly predicted treatment response at mid-treatment (p=.010), 1 week post-
treatment (p=.021), as well as 6 months post-treatment (p=.010; Table 3). Baseline 
depression severity (BDI2) also demonstrated a significant relationship with 
treatment response at mid-treatment (p=.001), and 1 week post-treatment (p=.041), 
but was not significant at 6 months post treatment (p=.281; Table 3). Finally, baseline 
general worry (PSWQ) significantly predicted treatment response at all three 
assessment points (mid-treatment: p=.004, 1 week post: p=.002, 6 months post: 
p=.019; Table 3). As such, these variables were included as covariates in the analyses. 
 Age was not associated with treatment response at any of the assessment time 
points (mid-treatment: p=.791, 1 week post: p=.604, 6 months post: p=.835; Table 3). 
Gender was also not a significant predictor of treatment response at any of the 
assessments (mid-treatment: p=.733, 1 week post: p=.105, 6 months post: p=.908; 






Table 3. Correlation table for all dependent, independent, and covariate variables 
 1 2 3 4 5 6 7 8 9 10 11 
Dependent Variables     
   1.  ASI Mid-treatment response 
   
        
   2.  ASI 1 week post response  .68*** 
  
        
   3.  ASI 6 months post response .59*** .70***          
Independent Variables     
   4. ICPS Theta-FN Gain -.43** -.41** -.26         
   5. ICPS Theta-FN Loss -.27† -.22 -.18 .59***        
   6. ICPS Theta-N2 Go -.44** -.41** -.19 .69*** .63***       
Potential Covariates     
   7. Baseline ASI severity -.32* -.31* -.38* .14 .32* .45**      
   8. Depression (BDI2) -.42** -.28* -.17 .12 .15 .31* .50**     
   9. General worry (PSWQ) -.36** -.41** -.35* -.01 .20 .29* .66*** .57***    
   10. Age -.04 -.08 -.03 .23† .01 .13 .06 .13 -.17   
   11. Gender -.05 -.23 -.02 -.12 -.03 -.05 .20 .33** .40** -.22†  






Incremental validity: Partial correlations 
 
 Partial spearman correlations were computed after adding baseline ASI 
severity, depression, and general worry as covariates. As shown in Table 4, results 
indicate ICPS Theta-FN to gains remains significant as a predictor of treatment 
response at mid-treatment (p=.001), 1 week post-treatment (p=.002), as well as 6 
months after treatment has completed (p=.038). ICPS Theta-N2 to go’s also remains 
significant as a predictor of mid-treatment response (p=.030), but becomes non-
significant at the 1 week post-treatment (p=.247) and 6 months post-treatment 
assessments (p=.801). Finally, ICPS Theta-FN to losses remains non-significant at all 
three assessment time points (mid-treatment: p=.158, 1 week post: p=.375, 6 months 
post: p=.708).  
 
Table 4. Partial spearman correlations after including baseline severity, depression, 
and general worry as covariates 
 Treatment Response (% improvement) 
mid-tx 
(N=55) 
1 week post 
(N=49) 




Gain -.45** -.44** -.35* 
Loss -.20 -.13 -.07 
ICPS 
Theta-N2 
Go -.30* -.18 -.04 












Sensitivity of treatment prediction: Accuracy 
 
 Given the findings above that low pre-treatment theta phase synchrony during 
gain and go trials predicts better treatment outcomes, post-hoc sensitivity estimates 
were calculated. Using the median split, subjects were classified as ‘high’ or ‘low’ on 
ICPS Theta-FN Gain and ICPS Theta-N2 Go. Treatment response was also 
dichotomized into ‘Responder’ (>=50% improvement) and ‘Non-responder’ (<50% 
improvement) at 1 week post-treatment. As shown in Figure 10, 85% of individuals 
with low pre-treatment Theta-FN Gain phase synchrony were classified as 
responders, compared to 48% of individuals with high pre-treatment phase 
synchrony, a difference that was statistically significant (p=.013, Fisher’s Exact Test). 
A similar effect was found for pre-treatment Theta-N2 Go phase synchrony, where 
85% of individuals with low phase synchrony were classified as responders, 























Figure 10. Percentage of individuals who are classified as a treatment responder versus non-responder at 1 week post-treatment, based 
on their high and low pre-treatment theta phase synchrony during gains (left) and go’s (right). Low theta phase synchrony at baseline 





Shared versus unique MFTN effects 
 
 Given that ICPS Theta-FN Gain and ICPS Theta-N2 Go were both significant 
predictors of anxiety sensitivity treatment response, regressions were conducted to 
assess the unique versus shared contributions of each measure at all three assessment 
time points. As shown in Table 5, when both measures are entered into a multiple 
regression model, they each become non-significant in predicting treatment response, 
suggesting they have shared variance in relation to treatment outcomes. This shared 
variance effect was demonstrated at mid-treatment (Theta-FN Gain: p=.401, Theta-
N2 Go: p=.317), as well as 1 week post-treatment (Theta-FN Gain: p=.530, Theta-N2 
Go: p=.206), and 6 months post-treatment (Theta-FN Gain: p=.839, Theta-N2 Go: 
p=.292).  
 
Table 5. Multiple regressions with ICPS predictors of treatment response 
  
B t p partial r R
2
 
1. Mid-treatment response 
    
.14 
 ICPS theta-FN Gain -.18 -0.8 .401 -.12 
 
 ICPS theta-N2 Go -.22 -1.0 .317 -.15 
 
       
2. 1 week post-treatment  
    
.16 
 ICPS theta-FN Gain -.14 -0.6 .530 -.10 
 
 ICPS theta-N2 Go -.28 -1.3 .206 -.19 
 
       
3. 6 months post-treatment 
    
.07 
 ICPS theta-FN Gain -.04 -0.2 .839 -.04 
 





Chapter 5:  Discussion 
 
 Previous research has demonstrated that the anterior cingulate cortex is a 
consistent and robust predictor of treatment response. While this effect has been 
shown across multiple interventions, clinical populations, and imaging modalities 
(Pizzagali, 2010), it has not been assessed using task-based EEG paradigms. As a 
scalp recorded measure of underlying electrical impulses from populations of 
neurons, EEG has greater temporal resolution and represents a more portable and cost 
effective method of measuring brain activity compared to other imaging modalities.  
Despite these advantages and the ability to detect anterior cingulate activity through 
medial frontal theta ERPs (Cavanagh et al., 2012; Gehring & Willoughby, 2002; 
Hauser et al., 2014), these components have not been evaluated as predictors of 
treatment response. Further, there is a lack of research on the functional relationship 
between medial and lateral prefrontal regions, despite claims that these functional 
networks are implicated in treatment response. The current study therefore represents 
the first study to assess task-based medial frontal theta amplitude and medial to lateral 
prefrontal theta phase synchrony as predictors of treatment response.  
Amplitude 
 
Regarding amplitude, results indicated that contrary to the hypothesis, MFTN 
amplitude did not predict treatment response for any of the treatment groups relative 
to the control group. The effects were non-significant for both Theta-FN and Theta-




Regarding the lack of significant medial frontal theta amplitude effects, there 
are a number of possible explanations and interpretations, including the sample 
characteristics as well as the method of measurement.  First, non-significant 
amplitude effects could be attributed to timing differences between imaging 
modalities. Although MFTN reflects activity over dorsal ACC, the timescale of 
activation is in milliseconds (approximately 200-450 ms) after stimulus or feedback 
onset, compared to 5-7 seconds, which is the typical Blood Oxygen Level Dependent 
(BOLD) signal delay during fMRI studies. Based on these differences in 
methodologies, it is possible that the effects of ACC on predicting treatment 
outcomes cannot be well detected at high temporal resolutions.  Future research 
would benefit from the use of simultaneous EEG/fMRI to examine possible timing 
effects for ACC treatment prediction. 
Second, the lack of significant effects could be attributed to a suppression 
effect based on the heterogeneity of the sample. Contrary to most treatment studies 
which recruit individuals from one diagnostic category, the current study included 
individuals across a variety of diagnoses including Major Depressive Disorder, 
Generalized Anxiety Disorder, Social Phobia, Specific Phobia, Obsessive 
Compulsive Disorder, Post-traumatic Stress Disorder, and Substance use Disorder, 
among others. Although greater ACC generally predicts better treatment outcomes 
across populations, there are some caveats that require further attention. First, most of 
the treatment prediction literature has been done in depressed samples using 
medication studies, with a much smaller proportion conducted for psychotherapy 




studies suggest lower ACC activity predicted better psychotherapy response in 
depressed populations (Dichter, Felder, & Smoski, 2010; McGrath et al., 2014; Siegle 
et al., 2006, 2012). Since the current study utilizes a behavioral intervention similar to 
psychotherapy, it is possible that in the subset of individuals with depression, lower 
amplitude may have predicted better treatment response. 
Similarly for some anxiety disorders, the direction of effects may depend on 
the type of intervention (medication v. behavioral), as well as the sub-region of the 
ACC (dorsal v. ventral ACC). In the context of anxiety disorders, the majority of 
treatment prediction work has been done in Obsessive Compulsive Disorder (OCD). 
Since all of the studies in OCD have utilized a pharmacological intervention, as 
opposed to psychotherapy or behavioral treatments, it is unclear if the medication 
study results will translate to behavioral interventions. Second, within these 
medication studies, it has been suggested that different sub-regions of the ACC may 
predict treatment response in different directions (Hendler et al., 2003; Swedo et al., 
1989), such that lower dorsal ACC, but greater ventral ACC, predicts better 
medication outcomes in OCD. Given that MFTN primarily reflect dorsal ACC, it is 
possible that for the subset of subjects with OCD in the current sample, lower MFTN 
could have predicted better treatment response.  
Since the current study included individuals with depression and OCD, as well 
as other anxiety disorders, it is possible that low MFTN amplitude may predict 
treatment response for those with OCD or depression, while high MFTN amplitude 
may predict treatment response for those with other anxiety disorders (GAD, Social 




given the low sample sizes within each diagnostic category and treatment condition, 
additional tests could not be conducted to confirm or refute these potential 
explanations.  
Regarding diagnostic categories, it is also important to point out that with the 
publication of DSM-V in 2013, several modifications were made to the classification 
of disorders including separating anxiety disorders into the following categories: 
classical anxiety disorders, trauma and stressor related disorders, and obsessive 
compulsive related disorders. This classification change has effectively resulted in the 
removal of OCD and PTSD as ‘anxiety disorders’ and has now placed them in 
separate categories. This is relevant to the interpretation of non-significant amplitude 
effects because it suggests two things. First, there may be important qualitative 
distinctions between the categorization of PTSD, OCD, and anxiety, which may 
partially explain different ACC effects in treatment prediction. Second, with the 
removal of OCD under the umbrella of ‘anxiety disorders’, there are far fewer 
treatment prediction studies in this domain, which underscores the need for more 
research and suggests that directional hypotheses for this category may not be 
possible at this time. This theory is also partially supported by the present study, 
which found non-significant amplitude effects using a heterogeneous clinical sample. 
Taken together, the direction of ACC treatment prediction effects may be diagnostic 
specific. Future studies are needed to further test this potential explanation.   





Contrary to the non-significant MFTN amplitude results, phase synchrony 
demonstrated significant prediction effects. ICPS Theta-FN Gain and ICPS Theta-N2 
Go both significantly predicted treatment response, such that lower baseline medial to 
lateral prefrontal phase synchrony was associated with greater symptom 
improvement. This effect was specific to the gain and go conditions, as well as to the 
combined treatment group, relative to the anxiety-only, depression-only, and control 
treatment groups. As predictors, both ICPS variables demonstrated specificity, 
sensitivity, and incremental validity.  
Regarding specificity (i.e., prediction to one group versus the other/s), 
treatment prediction was demonstrated for the combined treatment group only. 
Because theta phase synchrony did not predict response in the control group, this 
indicates the prediction effect is specific to the intervention and not symptom 
alleviation over time. MFTN phase synchrony also did not predict to the anxiety or 
depression only treatment groups, although the effect was in the same direction. One 
explanation is that this could be due to differences in treatment efficacy across the 
groups. Since the combined treatment was the most effective, there may be more 
variance in symptom improvement to detect a prediction effect. Similarly, differences 
in the groups could be due to the amount of time spent in the intervention. Since the 
combined group spent approximately 50% more time undergoing the intervention 
components, this may be a factor contributing to the sensitivity of predicting 
outcomes. In addition, it could be related to the nature of the intervention and the 
combination of anxiety and depression treatment components, relative to undergoing 




differences, causal explanations for the group-specific prediction effect are not 
feasible. Future research would benefit from modifying the design of the treatment 
groups such that the groups have comparable treatment efficacy, similar time spent in 
the intervention, and similar treatment components.  
In addition to showing specificity of treatment prediction, MFTN phase 
synchrony demonstrated sensitivity in the form of reliability/consistency (e.g., similar 
effects across multiple time points) and accuracy (e.g., percent of individuals 
classified as responder versus non-responder). Consistency of treatment prediction 
was first demonstrated by a non-significant interaction with time in the linear mixed 
models. This suggests that the significant prediction effect from the two-way 
interaction was not differentially modulated by time. The consistency of treatment 
prediction across time was also corroborated by the correlations, which were 
significant or trend level at all three assessments. Consistency of treatment prediction 
is important because it not only suggests stability and reliability of the predictor, but 
it also demonstrates clinical utility by representing a marker of sustained symptom 
improvement. Sensitivity is also reflected by the accuracy of the predictor, or the 
extent to which it can differentiate responders versus non-responders. In this case, 
low MFTN phase synchrony demonstrated 85% accuracy in differentiating 
responders versus non-responders at the 1-week post treatment assessment. This level 
of accuracy is similar to other prediction estimates in the literature (85%; Furey et al., 
2012), and suggests MFTN phase synchrony is a viable predictor of anxiety treatment 
outcomes. Finally, this effect maintained significance even after controlling for 




demonstrating incremental validity and suggesting phase synchrony offers a unique 
approach above and beyond self-report measures.   
Interpretation: Direction and condition-specific effects 
Based on demonstrating the specificity, sensitivity, and incremental validity of 
medial frontal theta phase synchrony as a predictor of treatment outcomes, it is clear 
that this measure represents a promising predictor. However, further information is 
needed to understand what the effects represent and why they may predict better 
outcomes. As such, the first question to ask is ‘what does it mean to have low medial 
to lateral prefrontal phase synchrony?’ The second question for discussion is ‘what do 
the condition-specific effects (gain and go) represent?’ Regarding the former, 
evidence from basic science, individual difference research, and treatment prediction 
work points to a plausible interpretation: relative engagement of regulatory or 
cognitive control processes.  
 What does it mean to have low medial to lateral prefrontal phase synchrony? 
  Evidence from basic science research 
Evidence for the interpretation of low medial to lateral prefrontal phase 
synchrony is largely consistent across a number of cognitive control theories, starting 
with some of the earliest work by Miller and Cohen (2001). According to their 
seminal publication, the prefrontal cortex is the primary means by which cognitive 
control is executed. Further, the allocation of control often depends on signals from 
the anterior cingulate cortex, among other regions. Using a very simple train track 
analogy, the authors claim that activation in the ACC represents the detection of 




two trains headed for collision. The prefrontal cortex, on the other hand, represents a 
‘switch operator’ by which adjustments are made to the train tracks such that a 
collision may be avoided. These adjustments represent the implementation of 
cognitive control and may be globally represented as a ‘biasing influence’. The 
specific control response depends on the sensory, attention, and/or behavioral 
resources needed to achieve the intended outcome. Although overly simplistic and 
missing the influence of several other subcortical structures, the purpose of the 
analogy is to demonstrate an important coupling between medial and lateral 
prefrontal regions, whose functional co-activation represents the allocation of 
cognitive control resources.  
This work was extended in subsequent theories with a push toward more 
comprehensive models of cognitive control, taking into account outcome probability 
(Predicted Response Outcome model), cost-benefit analysis (Foraging Value Theory 
of task performance), and costs of effortful control (Expected Value of Control 
theory). Although these models differ in their level of complexity, they all claim a 
fundamental coupling between ACC and lateral prefrontal cortex in the detection and 
implementation of control.  
More recent empirical findings corroborate these theories and further 
demonstrate a ‘functional loop’ between medial and lateral PFC, suggesting that their 
co-activation represents cognitive control through the integration of reward 
expectations, learned rules, and strategy selection (Duverne & Koechlin, 2017). In 
coordination with the pre-supplementary motor area (pre-SMA), the ACC has been 




control paradigms (Botvinick et al., 2001; Holroyd & Coles, 2002), as well as during 
reward/motivational incentives (Kouneiher, Charron, & Koechlin, 2009).  In both 
paradigms, medial to lateral PFC functional connectivity was enhanced during 
components of the task requiring increased control or regulation of responses.  
The functional integration of medial and lateral PFC during cognitive control 
is also demonstrated using EEG phase synchrony measures. During trials which are 
conflicting, surprising, or represent a motivational incentive, studies show increased 
medial to lateral PFC theta phase synchrony (Hanslmayr et al., 2007; Luft, 2014; 
Smith et al., 2015). Similar results have been found during performance feedback 
tasks (Aviyente et al., 2017; Watts et al., 2018), as well as time estimation tasks (Van 
de Vijver et al., 2011), consistent with the notion that enhanced medial to lateral PFC 
theta phase synchrony indexes increased cognitive control or regulatory engagement. 
Applying these results to the current findings, it stands to reason that low phase 
synchrony would indicate less engagement of cognitive control resources. Indeed this 
relationship between low phase synchrony and reduced cognitive control has been 
shown in individual difference research as well as the Klumpp and colleagues (2016) 
treatment prediction study, as described in more detail below. 
Evidence from individual differences & treatment prediction work 
In the context of individual differences, Moran and colleagues found that 
anxiety was associated with cognitive control abnormalities, as reflected by low 
medial to lateral PFC theta phase synchrony following the commission of an error 
(Moran et al., 2014). Despite showing enhanced ERN amplitude, anxious individuals 
had low medial to lateral PFC phase synchrony and poorer post-error reaction times 




are enhanced in the context of anxiety, this ‘alarm signal’ is not being effectively 
transmitted to lateral PFC, and therefore does not translate into improved behavioral 
performance. Similar anxiety-related aberrations were found by Fitzergerald and 
colleagues (2013) who demonstrated that clinically anxious children had lower 
recruitment of cognitive control resources in lateral PFC during error processing. 
Another study using an emotional conflict task found that greater trait anxiety in 
adults was associated with lower functional connectivity between dorsal ACC and 
DLPFC, representing inefficient higher-order control (Comte et al., 2015). Taken 
together, these results suggest there are anxiety-related deficits in cognitive control, 
and that this may be partially reflected by lower medial to lateral PFC connectivity or 
phase synchrony.   
Extending these findings to treatment prediction work, we refer back to the 
Klumpp et al., 2016 study which is the only other study to assess functional 
connectivity between medial and lateral prefrontal regions as a predictor of treatment 
response. Using fMRI, they examined predictors of CBT response in individuals with 
social anxiety disorder and, similar to the current study, they found low functional 
connectivity predicted better outcomes. Specifically, results show that low functional 
connectivity between dorsal ACC and DLPFC during high cognitive load on a target 
detection task predicted significantly better treatment response. The authors 
concluded that low functional connectivity between medial and lateral PFC regions 
reflected poor regulatory ability, and suggested that these individuals may benefit the 




As the only study to directly assess functional connectivity as a predictor of 
anxiety treatment response, the Klumpp study lends support to the current findings 
and offers a potential explanation regarding why low functional connectivity is 
associated with better treatment outcomes. The authors claim that individuals with 
low pre-frontal functional connectivity benefitted more from the intervention because 
the cognitive behavioral treatment targeted the engagement of executive control 
processes. Specifically, CBT focuses on cognitive restructuring with an emphasis on 
altering maladaptive thoughts and behavior patterns by disputing negative beliefs and 
generating alternative responses. As such, it has been suggested that CBT draws upon 
executive functioning skills in a top-down manner (Mohlman & Gorman, 2005). 
Therefore, patients who have a deficit in this area may benefit more from the type of 
intervention that targets these cognitive processes. Although the current study does 
not employ CBT, it utilizes similar cognitive behavioral techniques such as 
challenging existing beliefs about anxiety through exposure exercises (e.g., CAST 
portion of the intervention), disputing maladaptive thoughts through education on the 
nature of stress and its effects on the body (e.g., psychoeducation portion), and 
practicing alternative responses/associations (e.g., CBM portion). Therefore, it is 
possible that individuals with low phase synchrony between medial and lateral PFC 
are benefiting more from this particular treatment because components of the 
intervention engage cognitive control and regulatory processes in an effort to reduce 
anxiety.  
 What do the condition-specific effects (gain and go) represent?  
 One additional area that requires further interpretation is why the ICPS 




to the loss and no-go conditions. This is an important question because traditionally 
the FN and N2 medial frontal theta components show exaggerated amplitudes under 
‘negative’ task conditions that may require an adjustment in behavior, such as 
punishment, loss, response inhibition, or conflict. However, given that previous 
studies have not evaluated these components in relation to predicting treatment 
outcomes, it is unclear if similar condition effects should be expected. Nevertheless, 
interpreting the condition specific results is important to generate additional insight 
into why certain individuals respond better to the treatment.  
As alluded to above, a growing body of evidence suggests that increased theta 
power and synchronization between medial to lateral PFC occurs when the 
performance monitoring system detects stimuli important for learning or behavioral  
change (e.g., loss feedback or no-go response inhibition; Cavanagh et al., 2009; 
Cohen & Cavanagh, 2011; Marco-Pallares et al., 2008; Watts et al., 2018). Although 
the magnitude of synchronization may depend on some individual differences, it is a 
relatively universal phenomenon to show co-activation between ACC and DLPFC 
during the most salient task conditions that require engagement of cognitive control 
mechanisms. As such, it is possible that a saturation effect may have occurred during 
processing loss and no-go stimuli, such that phase synchrony was universally 
enhanced across all subjects. As a result, there may not have been sufficient variance 
in the loss and no-go conditions to detect a treatment prediction effect.  
 Additionally, treatment prediction effects may depend on 1) the context of the 
stimulus and 2) individual differences in stimuli processing. Regarding the former, 




and found that treatment outcomes were predicted by low medial to lateral PFC 
connectivity, but only under high cognitive load conditions (Klumpp et al., 2017). In 
the task, participants were asked to press a button to indicate when a specific letter 
(e.g., ‘X’ or ‘N’) appeared on the screen. In the low load condition, the string of 
letters was comprised entirely of target letters (e.g., ‘XXXXXX’). In the high load 
condition, the string of letters included a single target letter and five non-target letters 
(e.g., ‘MXHKZW’). In both conditions, the string of letters was superimposed on a 
task-irrelevant face distractor. Interestingly, the low load condition did not show any 
predictive functional connectivity effects. However, under the high load condition, 
low functional connectivity between ACC and DLPFC predicted better outcomes. 
Although the Go/No-go task in the current study is not the same as the one described 
here, an argument can be made that the two task conditions (i.e., Go and No-go) bear 
some resemblance to the high and low load conditions. In the Go/No-go task in the 
current study, participants are presented briefly with a letter on the screen and must 
decide whether to press a button if it is a ‘Go’ trial (i.e., not the same letter as the 
previous trial), or to withhold a response if it is a ‘No-go’ trial (e.g., the same letter 
repeated).  In addition, during the ‘Go’ trials, participants must decide whether the 
letter presented corresponds to a right or left button press. Therefore, two decisions 
must be made during ‘Go’ trials: 1) to make a response or not, and 2) which button is 
the correct response. During ‘No-go’ trials however, participants do not engage in the 
second decision since the correct choice is to withhold a response. In this way, an 
argument can be made that the ‘Go’ trials may represent a relatively higher cognitive 




these trials. This type of interpretation would suggest the current results are in line 
with previous findings, and may further suggest that the complexity of the task and/or 
the level of cognitive effort needed to engage with a stimulus is predictive of 
treatment outcomes. Future studies could directly test this theory by utilizing an N-
back working memory task with various levels of complexity. If the above theory is 
true, lower phase synchrony during greater cognitive task demands (e.g., three-back) 
should predict better treatment outcomes to a similar cognitive behavioral 
intervention.   
 Although the above explanation is plausible for understanding the Go relative 
to No-go effects, it does not explain the Gain specific effects during the Gambling 
feedback task. For this effect, an additional interpretation is needed that focuses on 
individual differences in processing negative versus positive feedback. One of the 
most common underlying traits across anxiety and depressive disorders is a tendency 
to experience a negativity bias, in which there is a strong proclivity to ruminate and 
focus attention on negatively-valenced stimuli and experiences (Hansen & Hansen, 
1988; Ito et al., 1998). Negativity bias has also been associated with decreased 
activation of cortical regions such as DLPFC (Mayberg et al., 1999) and ACC 
(Drevets et al., 1997), but increased activation of limbic regions such as medial 
thalamus and amygdala (Siegle et al., 2002). Individuals with a negativity bias are 
further characterized by a vulnerability to psychological feedback, reflected by an 
increased responsiveness to aversive events, and a decreased sensitivity to anticipated 
(McFarland & Klein, 2009) or actual (Pizzagalli et al., 2008) rewards. Because 




et al., 2012), lower phase synchrony with this region during gain feedback may 
represent a disrupted regulatory ability for rewards. Therefore, by targeting and 
modifying negative cognitive biases toward a more positive or benign interpretation 
of information (i.e., CBM portion of the intervention), perhaps the current 
intervention is the most effective for individuals who have a negativity bias and 
deficit in reward-specific regulatory processes.  
Shared variance among MFTN Gain and Go conditions 
 
 Finally, regarding the secondary aim of the study, results show that medial 
frontal theta phase synchrony during the Gain and Go conditions demonstrates shared 
variance in predicting treatment outcomes. Although these components are elicited in 
different tasks, their shared variance suggests a similar mechanism through which 
treatment outcomes are informed. That is, lower synchronization between medial to 
lateral prefrontal regions is common across both conditions and is similarly 
associated with better treatment outcomes. While there is some evidence for context 
specific effects (gain and go conditions relative to loss and no-go), the shared 
variance across these conditions may represent a task-independent function of medial 
to lateral PFC phase synchrony. This result is consistent with other studies in the 
literature that suggest MFTN represent a shared process in relation to motivationally 
significant outcomes (Cavanagh et al., 2012; Cavanagh & Shackman, 2015).  
To better understand the nature of the shared variance across gain and go 
phase synchrony in treatment prediction, we may refer to relevant theories of 
cognitive control. Although there are a number of cognitive control theories (e.g., 




they largely focus on an integrative and context independent function of ACC/PFC 
engagement. While necessary for understanding general mechanisms behind the 
recruitment of control, they do not differentiate types of control based on specific 
conditions (i.e., similarities between gain and go versus loss and no-go). For these 
purposes, we turn to the Dual Mechanisms of Control (DMC) theory (Braver, 2012; 
Braver, Gray, & Burgess, 2007), which could be viewed as consistent with and 
complimentary to the Expected Value of Control theory (EVC; Shenhav, Botvinick, 
& Cohen, 2013). The DMC theory postulates that cognitive control is supported by at 
least two mechanisms: proactive control and reactive control. Proactive control 
represents sustained and anticipatory maintenance of goal-relevant information, 
including support for task relevant goals and optimizing performance. This type of 
control is resource intensive and reflects reward processing (e.g., gain feedback) as 
well as active maintenance of task goals (e.g., press the button for a Go stimulus) and 
is particularly suitable to tasks that elicit high cognitive demand (Braver et al., 2012).  
Reactive control, on the other hand, reflects the triggering of control mechanisms, 
such as retrieval of task sets or goals when conflict or adverse outcomes are identified 
(e.g., no-go and loss stimuli). Both types of control call upon activation in DLPFC 
(Jimura et al., 2010), among other regions such as ventrolateral PFC and parietal 
cortex (Locke & Braver, 2008). In relation to other prominent theories of cognitive 
control, these two types of control are consistent with the ‘signal’ and ‘state’ variables 
described in the Expected Value of Control theory (EVC; Shenhav, Botvinick, & 
Cohen, 2013).  In the EVC theory, the ‘signal’ is a control process that maintains 




in the current situation (e.g., motivation, task difficulty, declining performance, etc.) 
that indicates a new control signal is needed (Shenhav, Botvinick, & Cohen, 2013).  
Directly relevant to the current findings, previous research shows the two 
types of control (proactive v. reactive) are differentially utilized in individuals with 
anxiety. Using a working memory N-back task, Fales and colleagues (2008) found 
that anxiety was associated with a neural signature of increased reactive control and 
reduced proactive control (i.e., high transient activity and low sustained activity in 
cognitive control networks), particularly on high interference trials. In other words, 
anxiety was associated with a reduction in the capacity to actively maintain task 
goals, presumably because more cognitive resources are taken up with internal 
attentional focus toward unrelated thoughts (i.e., worry and rumination). Taken 
together with the results from the present study, it is possible that low phase 
synchrony in the gain and go conditions reflects less engagement of proactive control 
mechanisms. Since the current intervention works to reduce anxiety, a reduction in 
anxious symptoms may translate to increased availability of cognitive resources 
needed to implement proactive control. Therefore individuals with lower pre-
treatment engagement of proactive control may have more room to benefit from the 
current intervention.  
Limitations and future directions 
 
There are several limitations that should be acknowledged when interpreting 
the results from the current study. First, the ERN could not be assessed due to an 




that has been strongly associated with anxiety and specifically tied to 
endogenous/internal sensitivities to performance monitoring, the ERN may have been 
particularly related to symptom improvement in the anxiety sensitivity treatment 
outcome measure. As such, evaluating the ERN as a predictor of treatment response 
represents an untapped area of research that future studies will need to examine. 
Additionally, testing modulation in MFTN before and after the intervention was not 
possible due to a limited sample size. Therefore, it is unknown if changes in 
amplitude or phase synchrony occur as a result of the intervention. This is an 
important area to build upon for future research because if the significant predictors 
of treatment response demonstrate change after the intervention, this would provide 
additional evidence that the treatment works for certain individuals as a function of 
targeting specific neural networks and cognitive processes. Moreover, it is unclear if 
the non-significant amplitude results represent a lack of treatment prediction 
potential, or if they are the result of a suppression effect from a heterogeneous 
sample. Finally, the intervention includes multiple treatment components and a lack 
of behavioral data to prove the efficacy of each individual component in relation to 
the others. There was also a lack of a standardized treatment comparison group, such 
as Cognitive Behavioral Therapy or a proven pharmacological intervention. As such 
it is unknown if the current predictors are specific to this particular type of treatment, 
or if they would predict outcomes to other classes of interventions as well. Future 
research should expand upon the current study by testing medial frontal theta ERPs 




 Despite the above limitations, results of the current study represent a 
promising avenue for future treatment prediction research. As the first study to 
examine task-based medial frontal theta components as predictors of treatment 
response, the current findings reflect a novel contribution at the forefront of an 
emerging field. The results also provide additional support for a convergent medial 
frontal theta process, and suggest that low engagement of regulatory and proactive 
control mechanisms is predictive of better response to cognitive behavioral 
interventions. As such, this work may ultimately lead to the improvement in treatment 
efficacy by serving as a target for future interventions and a method of improving 
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